var title_f3_15_3312="Trichuriasis scope";
var content_f3_15_3312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trichuriasis scope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 300px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEsASwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5xbGDTF5oblqcFxURZpYUYxRxnqKUDpTtg7UmxrclAGKUAZ6UYxilHLH3rOVjZITsPWnjoD3pNuQDUgU7fwpq1i0gXHenHPbpTAM1IeIevSs2uwMr8mnLGGHPH1pyxnrkVMiDHNacyRNmIgO3mlwc9Km8tgm4jApo64rOUtC+UBnA9anREaMlgeRgEetLHDvTI61dWaEWyxXNuZOch9+CB6YrPyHZmJcp5cjKvIB6jvUW0elT3LrvbaDtzxk5qGuhbWM2mAUHPy0scfzA9achwOlT2kbMc44qJ6LUcUyaGPOMDFXYl2jBHFNRAuMVYj+c1xtNs6YbFdwc9DTCKvTpkAjjFVGXknihIoaFHcVEV56U8Fj1pasCIxkDPWpEB44pw5NPUYzWbQ47jh2rU01FlIDYJrLPGPerFvO0bqU4INYVk2tDem0pamw8Wxx2WgdavwhLuDKDJUfMc9DWex8tmDcYritZ6nr0HF6lxAOMdasw/fFUYp04bOKl+1xD+MCsJKVz0Yyp26GqigjkVYjToAtYq6lCD9/p705tbgR8mQHtis3GfS5arUkt0dDGp54qRYxjkCuYfxLCpwAKb/wk0XoKiVCtJC+t0EeSn79SUKp20qdT9K+0PzoTsalQZBJ60wKTIasLyRjsKHsNbgoyAT1pvQ0/NPrJuxtEEA2ikJOcD6U4fL1qQICQ3tU8xYwIVUE9TTZCdjCp34FQ7CeeMVZXKOX7lPT7tCIoUe5xTiuDgVlzcwcpKzFlAY8U3aOtPCZxnGKkWIDrU8yNVC4IxVRg4pkpO0c9KfgZx26USwZTNSpa3BwaMyTliKbUrxjdTQjMOO/FdEXzK5k4k9tHvO0VqW8ZjGD1p2m2pCDjqKupCFl+bofSueUuZ2N6dOyuyjGM5J65pysVbjpmpblBGxwD1qBuWpDe5M0u7rTHA2EgVHUidKBEZANJ5eelWEiDAEA4p8lsUxkVLdgKgUA0tWDFjkU3YNwJpOVxx3GbQQM9aeqYPPSp/IX6GllhMJGWzmspGltbk1rdm1kGCcd6S/u1nkYjvVKXoKY/Ss/Zps2VVpWQSXDKODVWSds4yalcEjAqu/3TW1OCiZTqytuRvOQRgnmmmZjyTQwJqMjqK7IwVtjn5muo7ze+T+dL5vufzqHafajafajkByuUOi/hTU6n6U7qOKkQYHIroPOEjALd6mUYPFCL8uQKcqnPIrOTNYxG4xTwvp1p35UDrxUxV9zVIcgPO4VKqggUqjCjIpT0qJaFpEMnBxQn3acQSRgZqVV4HFLntEqzEiT5RmpTz2qTIKYHWmOcLzwaz9p5FqI7AUfNwaDJnGKgeQsR6U5eKnQuN7jwfmH1qV2ymOKhX7wqcDHUcUm+xutdzPdB5gqzp1tvmwajYfMa2tFtsxNJ1PSq57K1zN0tbl2GPYuEHT1pXZRJ9KnijGc54qtcxhX3DqeorNd0PUrXTCQMMDmqewDaPWrTqc9KaIuRnirTVhWRVcHOFqW0jd5QuOKcygMcc1YsXEb/ADL+NTcVkatraBY88GobqIgZxVq1mVuAe1TvF5g9TSBJHOy8UwKG5PY1qXdkQ2QKqPCy9FoE1bYYGO4Co5mJIB7Gp4gA2D36+1RXMQibd2NTI0exXcZYiiVCCAemKUgluBSyZx3z6Ukm3YxbdyBhg1WlUDgd60vs0+QDC+SMjI6iqUyMsuGGCOtacrjuQ22VGGDTCoJ71adc9BUbDg1vGWhJXYYptTbT6UhGOtaRfcRkqOQKnUAe9AQcYWpUQk/dNXOSOaMQX7vpS08R/LzxSIM9sisr63NRtSImWFLt9qmix5o6UTn2KiKUIOD2pCvXmrDYLjuKZKuG4Heo5rmy2K4GKnRcpmmleRgVMBgYxiobsXHciU4PNNmO44FSsFx0FRpHlvalzGghQFcDrT41PTbmpki+Yc1LHGMdRmoGtyNVOQNop7KcHPFWFQDBzTJ87T19qTdjRK5T2jNdXpcQSwT5eorlwCWAAz9K6+AFbZFB6KOKyk7tGnLoRY+9jtVO7zu4rci0+WTT7i9WFjBCQJHBA256cZ5rLaAseeuetWnYjlKYTC5aonUHnpir0ijcQBkDioHjwCahy1M3HUolMEnNR7iGJqdlJz2qLysKxJ/Gqg7szauSWt4ocAkg1uWzlgDnNcjOSJM8+tb+h3PmrsY5IHetAitbHRQIHHzDJqO7tV8s4XFXLJMpnH41JcQsV7mp5i+U5KW3ZXPfmm3CNJERtyR0rVvAFfHviooU3vgU07sGrGBjadpK/nXe+EPBkfiLR77VpL1bWGzXhAuA2ATzn6Vu6h4d8Laj4Ee90Jdur2qK1wC7E575zxXnMLX502S3t7iRLNifMjRsZ+uOv0qtnoc71ud1J400FvCr2Ulqp1AKFhCQyAqe5Len0rzDUisk5df4uorstM8CT3+jS35dQEXdknHFYV9oM9paec4LIehzmqab3BKxzoOQRTCpA9qs+Sc4GcmoirZIyT7U1oJohppXJ61Nsz2xSiMj+HP4VfMJqxlg4/Cp4/m5qpu556VLFKM47Vo4vocqdiabpRDymajmkB4HWpIuFxUu6NEPp6Abs47UwcnHapSx29RWbdzRKwqkDk1FJMWORwKOsbE9QOKiRCXI/hFA0x8cmHJPOatKd/I4qsseSMVciQANnqKmUk1obQ3Gcd6U47USABeKi3GoOhxRYBFOVsVWXIYGpkOaTkraF06N1cmBPrxSzOCBwajUnIFPC7yBUN3N40ktx9jHulU46HNdNbjKZHT0rHs4wmMda37CNW2xsMknucVk3qU4qxavJhBpm2PzF8wEOh6MOxrMtJ2t5FlwrFSDtYZBp+t3G6VYgc7Bt65qpNIFCBvvGjmZnyolu5zdXcs7IiGQ52oMAVTmO4kUrTfLkVXaXqe9LczlTb2Bk+U81XkwEwTT2n+U1SlcsTzxWlPcy5GtyG55YH8KsaJIU1BR/C3Bqs3zdas6VHm+jI65ArYhqzuj0TTseVg1pNCCox3FZ9ku6RVroY4PlrM0OT1K22HO0mqKRNGhIHNdXqVqTGWPY1miDKkYp3drA1cwcXJVoYbm4hglI82JHIVx/tDPNd3Lp+m2fhBzbL5kzrl5C2Nv19Ky9Ct9M/tSNdXuTBC4IXHBZvT3q14fWztNditvEUTf2TJKS4uF2ArztLBsYFa0Um7Mwmkk2V7DcPD1zb2GoRMhQkhvmI9gexrlit7eyxWbSeYp42qOc+nWvSPENx4Fi8Qz/ZLS1axjgIaS2XMckmOApGQTzXnctzEzyyWUbKpYspPUDFVO0XZO4o8skmS6P4Q1HWdSex0+FTImcs5wB681jeI9Gk0XUntLkASrwQDmtfRPEGraLcPPpkiRzMpDGQbgfw7msPVrq5v72W6vZjLNIxZ3Pr/Sp5huKL+g+C9a8QWwn0q1EkY5Yk4xWVeaXdWVzJbTx4liYqwGTzXeeBtfvPD+g3klrMPLkXBDDO09iKytM1uwWKV9TtmnuZZWkZ/XP0rROMtEQrdTyINuB9alVSVGBUYQrtIHX1rctNPk+zea23nsK6Kk1Hc44xctEZcUbbulWTmNS3tWkluACQOlZ1+CjnPSso1Od+RpytFcXOAM1KJCSPQ1WWIsoNXbaDfjdn8KqfLHYai0xXB8oL3zUsCn7vfFJJG2QPersSCMAt6cVjJ3N07jFRQn+3Q745brT4kMjMfUcVXnbj5elYRV2bp2It+etG4ZxUdAP7w+1acrLTuTDhhU0Y5FMRN31q7BCQRWdTRWOigrhEhYn3q1EgjGO5pyWxBDZPPPSpvJYnoePQVznVFWHWyAyEnrW/od/Np2oQ3aKCYwRggEEntz/SsWFDH8zZBNdPMmlT6FBPp8VxDdwjF15jEq59Rk8UEuSehzd27NdvJIcszFiR7mqk8hkkBarEv76dioO3pUDIC3NTzIuMWRH1pkik8+lSuoGMUu0bd1UmU4LczidzHANMZSTmroiGeBS+UcVbmkcck3Izwu44rY8OWRmvA+3hOaLPTpbiQJEuS3Feh6DoJs4FDKC7DFCmmJxaGaRDi46GupW3UqNwOQKbp+lNFIGZeTW01scDIHSnzIi5zOpW/7hgBzg4rDhhZSRIMYrs7+IdO9Yl1ZO2eoH0o5kTJXOg+HNto893d/2nbRtMqgpK6kgL9egPvXOeOtVOr+IJrXThbSwQny0mTkMB1GfaqVpq91ockyQMCZVKFSOCPoeDWZYadezzboIZBbtks8IwFHfitpVeaKVjP2DUnO5rXn9gWngRLd5o59VLfcCkleeegri7e3KtkKVXqR0rtrbw9o0+oWhmu2hhbncR3HY+9UteGneWwVN8ySbUcHhh71k2kUlc5O7fzZBHbR/vG4461VttMkufMEeXZQSQelaFzeNFcJcWy7WXjGMil0HVbnTbyaaII0cmVl3dBn2oi77EuDNXw7odk2gz3uo3iIu7Cw5I5/Ouc1G0tRckW7jy8cVDdSG4mfHKlshRwM/Sm/Y5m5cYY84Naqp/MTys4KP96+3sDW3pl2DGyE8rxWE/yDI61cs3AXIPOK7K8HJaHm05JS1OiC7xu6Zqhq8IOCOma0LOQPaoMdB19ai1naRCVHXIIrzotxlY6bJmZDGMgdm4q8kGwhV6U2NMDIXPFbOn2wk++QBjgmnWqWtcuCRl+RmQADJHWpLmMFAo65rbnsWtZsyoylhkBlxxVCZFNwFx3rOE3JmvInqU1HlIWHQjFZEhzJn3rT1DKZUHjNZR6mummuoAQD1OKVYm3KEVmYnAAGSam022nv7tLezQyTvwFHUe9e1+DPAlvpUazXQ828YZZnPCn2pVKqpmlOLlsef6F4L1G6VJblPIjPZskn9K7TT/BsEIUyRmRvcV6NBbRbsBlGOqrV+K3QY4z9a8+dRyOyEPZ7nn6aNbQfL9jQDpuKA4qxFoVtdAkxoD0AAxXeyWiSZyuf61WGmoh3IuOc1Ki3sa+0icBqPhFNqsiL9KybvwvPEj7FzkdsivXo4A6jeOar3Nlnhs4PFLVBzxPDX0mS3yWUk+3NUpLM79y8V7oPD0G/cYwwPOOtUNU8P2jMALdFJ7gU7y6lRqRPGRaseo3fQU4WDN/Cw/CvZY/CNn5O6OIB8dRVWPwvGJssg5OSM0nzPYr2kTyiPSJCTgfmK1tN8J3V2egA+hr1saBaQwDbCC3fNaem2HkphUC57elOKmYTnHc4bR/CcdjHuVVMi4yfWuottNDKrFUFdIlqMFSAR9KkW3CrgAV0QhJo5XWTMYWYGKl+yqzcc84rUNvuHTNW9M0n5nuLzY8JX5FGcr71vToOZhVxMKe+5ydxpyvLubgdqpXdkkKsWPFdPdiNt7xfcPK8Y4rj/GOopaWxQcuf0rCfu3NqbdTVI43xJeRXt/GsUSxJEuxmHVjU2jajqVhF5UF2kMcx2fOmSB6jkc1iSuZGeTHJOcCrOp32hroVjGssp1dGIYbCAAfcgVnC8jeS5WkZl5K4u/La485EY/MRgt71ek0yS7lxYJLc4IyFBIFO0zTory6O+QwR5yznOBW/YXp8Ma35BulurUxfO8K5x+ParSa3IkcBfwPDK6Ou1gxyPeo1Rv7MmZEDDIya17mGPU9ZlKPhJHLDdxgE1nX9tJY3Mls7YVjkYbIxVRdmSMurOK3sre6BBkYhgvrWhDqlpcp5k8QjfptVQRUN1DFdW1useQxQKM9DWFcQmKVkAPHoa1SuJRR55O4ztxU1qjMCASvHWqr/ADy8dq0bZCseTXqS0jqeHa8kbemSf6KFx8w4NTalbyNFE5Xau/b156VQsGMbqDwD1rZuZYnhjIwACK82as7nbDRalS1xv8p+xxz3roLTaISOMYrBwGvY9vcE4roLK33RLgNXLXk3a5rTWo2RpXZGdtyquPnOfwrOlfMzEL0PFa16BEhDDGBWBLdEZCDg96mknc3kUtRfMpB4AFZjEliBz2rRvEY8k8mtT4f6OuseJYY5kLQW5Mz49q7ozUYszUHJpHpXww8MJpumJdXSr9unUHn+Fewrv3wImweRVS3R1OQcIDtC46CtGJFYkhCT+leVOo5u56kYKKsjMto/s9w8pbJbpzWgupqrKHQg1ZeMcMUGB7U2JrfcvnYWNuDgc5rGnK8rXHJprXU0La6jnxsJ56Yq+ke5awprVba5JtmbaCCPpWtaXIwokPzGuym9TkqK6vEtpaggHAzTvIHcCrELipyi1u463scUqkkUhb5HA/IVA9kryhiBx7VqqAOlAjB6cGpa7kqs0UFtM9OlJ9jRWycZrRWPHGaVoAxHNCimS67Kf2ZSo+UH8KkSIAfdGauhAq+tRkZORwKuMOUn2zZCsYB5p20H+EVIEzxmnBCB1qyXIWCFMguBtzUGqzS3DrHbTGKFT82FB3e3tUkjFTgNxWXql9DZxM8pAHrmqjX9nGxMKLqyT6lTUpZPLIt4WllOdsadSR2ryrVbyTUFa4lRgrkrtcAFSO3Br0vw1rEeoakzW6yCYZCbh8hGO5+tebX2j6rpd9cWmtSQTXB/fF4WLD5iTzwMHmssTH91zI9XDT5avsp6aGbY29q0zLeS+Vb9S4Ga2pdX0HRrK7sLaCK5mlRXWZo87c+9UraWztYZkvIFmZx8uegol8GyyeGl1e2vInVuZIVQAqO31+lc9D3k2jfERjFpNlzUtCh+y2N3HqsIt7tQJolP3emcUtxY2GkrLFpV5BKzD955jE8flXn7rLaNJGqBHQncpUAqT+FLb27ySq7Ry5kH3gK1Zj7LzNPVdLltoxeggQTfKME5rHml+0yp5hwPU9Ks6hcXMcDWsmVSM/KD61lXCSAhSrLnpkYyKaTYmraFi5v5AqQJs2Rn5SBimeQ0gDO4VvoaWLTsxGWU4AOME8mro0TUiqtsARhlemcfnW603Jk7I8eh5k981v2savtDHAAyaybaLCFzV2CQxjOD7131otrc8eK2ZqsgY5Q8DpVS7Z/OVBycZqT7dHHAu0Zb071HEZA+ZQp3nIyelcaTSuzoTvoaGmsXmVmGGXAFdvo7I0ZQNznpXIxxpFCrlupGDWzazBR5sTALjNcdaLeqOiKtZGlr6bIJDwTiuS8pWcADoK1dRvXljdQcg1QtfmYfSlT91G8tynfKQo3dO1ek/B6w8vTbm5I5uJtqnvhR/jXB6xEDFu7AV698PYBB4W00AfNsDn8TmqnP3S6SvI6+OAsdo7Hn61oW0Xl8EdeaSzRFAZ2UMxycmtG2RTmXIKe/SuONNt2RtVqNCJB8uXwPasvVTb2kRdlAHX1q8Lhp7iREJCKMhscVw3iLVYLm/mikinZotvluGG0euaddRpxTRFGTcrsuHxKgbake8dKtwa7FIPulXrmLe3SVN64GOatQKkChnwea5FXad0ei6UWdzYapGVUM/NbkNyrcq2favLpJBLGHjbYykjIJHetGDVDbxIFmZnHYHiumGM1SaOSpgPabHpQIIBFPTqK8/i8Z/ZnVZ1IX1zxWrp3jCxuukp/4EOP5V1e3jLc8+pgK0Oh1/HWnjtWFFr1k5x58YJ7A1aXV7XHM8f8A30KqM4p3uczoVOqNQ4IpoVazn1ezQZa4i/76FU7rxJYRRFxcQ4HH3hmtPaw7kKhN7I3WAUZHFV57gQjJK/jXH33jCNIz9nV5D/s5H8xXKaj4k1G8G1j5Kk8Bev51zTxtOG53UctqVN9Ed5qGv2cU4he4jRmzyzgAYrzzVtVuNRuli3pIm7cNh69elY984dT5gkkGOQTkn2rT/tSzVhdWcLRzecCIpFyFQLjAx0J965lXVRaux6UMKqMkoq5PpWo3OnXiXFsiNJggxyfKM1Zk0ltOtZp5rm1MupusshWIjbn3z2rES8a5vpJGXyw7FtvXGT0rQvrrUZrY6dZxvchsBV2dyf7x7VUXOacVqFSl7/tNjI1WyNjeyQGUS5O4MO4NWvCGuR6LqXm3STz2WCZFiQuy4/2R70zUtDm024aPW3a2UozhkJckjt3rltK1++0u6eWyVCXTayyLuyK2p050tXpYmpT9rDTW56X4ki0bWtUS/wBEu7aSe9GJEkI+TAHbsfasrxhexwS2gku4ZpktwjC3T5VbPA6mvPptSuWkaQgRO5JYx/LyfSqpvbx0B+Z3Bypb1B4zXTCtzfEYRwcoqyOj1/w3qVroKa3cTwvFI2fLJwf1rkNQ1SW4VWlZTKg2hVA+UCrXiHU9W165SXUZPlVQoiTITgdl6ZrBa0nTkoc1fPDuWsPNLU0xcBrZMzsHd/mHark2omFhHbXytEo4J4Nc75MuCXUgCnKCBgim5c2iEqMuqOdtgCSP4c1PdMFhxGBTbVwbeMbFBTPP97Jq3dW5FpE2MeY5A98da7nUtozw4LQzLZGMnzAbq1Le2O0uRzWhY6Xi3WRyvLDg9RWmtpCscpcHeFwmOlctSutkbxhszOtLNWAZ2yewY5A/Ct5ra1OiT7buOO4GW4BJfGPk/rmq8VqWYFRu4yxAxRPbFLSR9ozj8a5Pac0rHRFFJID9n35JwQDmprOEtJle44qaJN8IUn5VTLCktAQ2cY5xUuVma20IdWQm2dT1xXuHhCDZoFioHAgT+QryLUYxJYy4Az2r2LwiCdDs9pz+5X+VKc1JWRVO9zoyFWzZiu4hD9atG1i097OGIspltjNIjMW5yvr25qCJWeBgHUuCCpK5Gfp3q3qXmXWpw3IO2JIBCVMYBJLZJ9hx0p05qEJLqzKq5+0S6Dbq5SG0Y8KmecD2rzKKzNxHIzORvcvn2ya9C1UeZAUAwiISa4eaPOmxYOCynn2BPFcOJ5pLlZ6GFhG12hkOyCZo0/eLntUt5IkrfImAAOMd6oQ4gbCeuKBKRIc5zXIoOOh6NNLqMmlZFk28cZquJmBXIIGKklbc5Y9DTYoJJ2aQIxVP5VblyLU2SQ2WQNKoz82M1YjCJGWjKK46r609rNMq6kFiAcVDFFmbYpyT1HepU20ymuwEeYdzdu44xSPGj7Ssr5X/AGzV5Y1CFT3601bNQjMeAehrNV5LS5FkZlzIDwzuR7saXToY9+4c59easyWnUgZFJFBKjqy/Kvqav2tupz8ictjRVgiuCQqioZQssQIccd6SR0e2ZJDtJPFNii2weU2woTnIHzfnWcpcxryjJLYSRbyQynoKhit2YsATgVeQFSEQ8e9LYmCeZ4mvIrRunmSDIzTp023ZMXMoK8tjNktZFj4wCT1rf07xlPpmjS2rWKNOEEccgJAP+8cZH4U1fCr30a3Np4ptXgjyZYVswQf+B7uPyrF1Nw0wSJIgkQ2lkXBY+tei/bYOzlY54uljnyWasZ9/cXmolpdQumkPQDccKM54zWBqVwquFTHHGRWpfN1SPpWLPalweDgVEazqPmk9zonGNGNodCtJdDoxqxDcwhOpyKoTWpVuhxVeQEDBrTfZmMcRbdGw11G3SonuEJrIyfeo2LZJAJ/GtFTfcbxCNaR4pV2kgVAbSJjk5P0NZxeXIwCPrUgnYcEnNUlOGqZk66e6Ob06EzPFEhG5sDJIAHPr2rT1WFUvIFT/AFafIoD7h7modHtwqr5mB3yas3gCvb5wcZ49K9OpK1z5qGx1tnBu0yJi0BEjEABgXUqM8r1AoksldAFk5PPAqrpcyNasQFJOASOprYiyyrjkhj+VebOfKztpKMiOzsHllSOMR8/LlzgHioJYzDHOrY3uCPXH0rXt4xI7AcuMFBWZfA+ewI6enSudNyldGzilsY1rFst5AvI24NW7eDEWe9OtV+Rxt4LGr8SjywuMGtJSGo3IlhaS3xjrkV6Z4IkLaJaYOWVApH04rhI1EagevT/Gu3+Hzp/ZrI2dySMPrnkCpjK5pGHK7nYWrSeaQvGauzbggBZvXrVe2GZeDjg1cIXA3knmqbsRU3Iri33wDe2Nw59xXCYtorm9hIkLQnMKshZTk+1d5extIVAG2MDn1rldYaOLVVEYA3JyPUiprGmGu3Y5fBG8oFVs5IAwB7ewp7R3KEJcoiOwzhJA+R68UrSCOWXC8sScUb8uHPGRWScVFprU9dQejKxQZ2swUVqFvJsUSF924HIU81G8atEScZqv0BA4HWuWcbu5tYjtZZhLuLIQp446U9XdrpnZiWPWq7PgkEZrQ0tI57pAwG0r0qeayFe2pPCPMAwtWUtTMux8YB4+lXpbGOGN2jIHGevSm5iRiVPz47Vztake0UtiOS32QBV7e3Wq02JYwEQcd60o2MoxkGlW2ijO0Ag1FROKuiObldmc/cJsiZumOaDFIoXIJ3cjPXFb8lijJhc9eaeulLDbrMzh1dyAOc5rGMpSV0KVeMbX6mGsZiMTFSxJ6dh9amnt/KCSIGjBJIljXjP1rotNbTILC+uLqQeZGCoDZOD2x61gS3AnZmVdkbnOwMSP1rsVNUUnczpVfaVHC23cyJ7KEyefclridefNdsH9MCqFzNneABwOMVs3iO3yqDzVe30d3ILjJJ+lDxXtJXk9Du5YxjeJiadafaZvMlTADYrWutPjeIhI+fpW1DpSwRgquB1696tGFABvPGP1qZV4rSJzVHfzOEuNJyPudKy7rSTtPyj8OtekG1jbkcj3plxYIRgACs44qSZDpJo8om01933SMe1MTTHJOQeK9EutKB5xmqLWKpkcZ9K7I41tGMqSucZ/ZR9D+NRtph3H5a7M2vykkYx+tVHX5j8tdNOvKWtzKUTypm2ptQ/lVaGVzcKX3MM4q3sCP04IpmxVOQMHNe2leLPnU7G7p0gXYqjCA5PvXS2e5smIF8Lk49K5XTxkIOxPNdRpLCI8OUBGMjv7V5tey3O6hsbNuZIhiHh25B9KqTragWs0U7SXLoxkgK48tskYPvj0rfsLVLhZFkuo7f5d4Z8Zc5ACqO5PpRq8LG+jt5bmWOGCMwo8kWSuOSAueea502tUbyOTljPmjCbQ/bOagVTJMpJICmtG+aJNQl+yxTJCcMqTHLDjr0HU+1VoR5hO0bT3raOquzWCVi05yqEHpXTeAp1W4uoWbnAkAz1NcipZB83POK0PDl0tvrkDno/7s/jx/SplJmiV2exWbh5ePQ1c/vehI5rK0uRfMHHJGK2AoYlDznmtLXMK2kiK88xwBEMgdTXMeJLNwI7lEAKE7seldhO4C4APSsHVInmgmUtjeuBmnVS5bjw0mmcJOv78HPWmuCSB29aLtifn5G07SKhNyQpANch7cLtGgZFMWByTUD5XI61RS4I571Zhuo3OXrnnJq5TqJKwyWBsbu2K0bJHhQSKPmVcCkiniaPGMgUsJBkKrJgelYKTe5nzp7F1L2Z48SDJJwcd6yhqpGpC2eFgxHGR94e1acDQ7wpb5weKSaytri9ja4iGUB2t9aG4x1kLla1Ro2QYxb9pHsetXQWLLypP61HCNkIihKhPcVH9ts7a4CTTxiU/dBI5qbSmrrYxlK+rNOzhxIpbBUkDaeKn1iOOK6lRFZI0OUUtkE464qKOYFmYNHtVQwJbvVXUJhPMNnGOT701anDXc41TdStd9DOW2VnyygknJyKtiBVVW2D6Yp6xuHOI5XxztVcmrD29/OvmWdqjBOXWSTY2PYY5NbRw868fdVzeriIw3dhYrRWKlowM9KvQ6ZEJAccntUOm6jE8SmaKRGPQOuCPqO1bETxsN6Nz2rya2HnTlZnJVrVDMurEFdiL07VnRWsS3KpfKwi/i211xh82LLsIgOSx71Xn0qRFWSWZWVhhht6e9ejh8POFJVWtDnhjbJwk9WcxJajc7wqRAT8mfSopIc8YrbvIBHLsRyyAYFU5ojmuarOLdkjvoV7oxnt/lYY71lXNowkJ28Y612en6Y9+7opVcckmqepac8JaHcDg9RS9jOKVR7GixEJSdO+px0sYKhcYxWTMgErfLmuh1GFo5to7VmSQ/OelddGpGL0LaVjxm44GfQVUiUzS4/GrE5812xxnoKksrcxsXPpzX1KaR82aWlqQ4A712lhZuyIQVLdOBXM6dA/nphCR1rt9ID7uFI28jivMxa5nodmHjfc19P0n+2FkH9uJpC2t0kc8kroCwZdwERI4f5T1yP1rJune2nvroaddR28dwA88k6XHmM4+Zi8fy4IA4GMe2a2nuLCPw3f2V3YNezXT7jtUFUwFAZskc9cEZ7+tUItYstOa6FzDfLHJAsMNpbouzIz1Gf1HYd6cJQlFQkieSpGo30OZvWFxd+ZGFCscKFztHoBVhLdoFdXUiTdtPpyKy7aUv85G1vv47A5PStbzHmcmRtxcgnPfilJWZ205c6IZolWKQxsTIzA7T0FR2uYZFYBt27J6fh+tXXiIAyeOwqaCNXxkCuZtLc1jF3PQ/DNyJ4Y2Y5Zl5/OurtvmfjsK878JSm2uBC569M/WvQrNj5jH2rootSWhz4pNK5akhTr3qpep+7wF3Z9quDLHHHNPWEsDmt2k1qcEZtPU848R6TOHM4jyrdhgY9/euVkikSQqw4HT5cV7fNpsc0ZV1LAjua5TV/Cjhi0BOzOdp7VxVKdnoe1hMxhL3KjPNriNmhOBVKNn3ZORg12dzpMsKkMn6Vhz6ZO7OVicDPpiuaXuvU9L3JXlFmYjSlmZXOKtxXUkcik9qmtLCRJCJFIJ7GpZ9P3cDikrPYtQbV0R2moH7Tl9vHHNdDZTJcKrKylwcYrlf7NkSTcDkDrV6CRrdMFC3pVciZLi7HXX1vaW8a3epX8MOmRAvcKuTIwH8KqvJ/AVmz6/aXd3ep4U8OOIp1jQahcgohVfWNsPwDgYxzycjFT2Vta3yiWN45pgQoklUKRnk4I7Vq2kU2worAkEgkdDz2rqWOdCHsqcFr1PDqYd1KnPOe3QoQwKQmz5wvHfrWlaWYZnlZljRRyWyc/Ss64vpr/VbTRor6y07cHG+OIlm46jK7Sw9CQKt2duk08trpd5JqAgULPcOuweYOvHTP04rOGWVkva25r9OpVTG/YejLEE1xHJm0laKTdjcq5B/OjU7pSqS6jNdi9tI2dWgjZiOOSVA6fWnpJOsSx+YPLzyuzqfqBUwu9U0+Rhp9pp87TFRI90752Z5GQD+RrqwNOLfI3ynPXUpLmUVco/uriyhltpBJDMoZXVs5H1HenwI4YBSeOmSTVibRrfTbiS4k1gpbM/7vTLaCMorN0VcDP58VZhs53mWK3C+cwLKH7D3x3rnxWAm6lk0/QqjjIzp+9oT2uoSxx+VIdyemK0I5vMTktj0zkVj/ZpTGssgIViRwOhBx/SpYJxAe5HSvKr4SrF6kyp056wV2XLiHeCaz5xkYwa17ZxMn3hg0y5tsjAArkcWtCIVOSVmYil0PyEpnqRmtKKyhv7YqZdkq8+5qOW3KDn8KgWR4myhww711UavIkp6o3neprB2ZzuoabIju2GYbiMmsp7U7uRiu6YLcxsrDLnvWFPZlJWXjirlT+1E66NW65ZbnzjOmJBxxmrtii7R3waqTgsFA61vaZFHlUPB4FfQ1alo8zPIpRV7GtpFqZTvxXW6dEI0ctwcDrVTSbZIkwCDnuK0rsYs5XjnSF1XPmtH5hH0jBy30FeTKrKrKyPSpWpxcuxBqsxt4N7CdY0jad5ETcI4wQC7c/KoyOazLxI5YvOt/3tsQMTLyrEjse9aGjy64XtZtE1OCe6cMAZbJ0WRCOd8RbcpBHHOOlZur3d88tr/aSTq1xF56tIMeYFYqWx257fjXY6MI0+ZSvJbmCrtyfNs9u5gQxmNmwMk1cnlYzo4GD0x7U2cr5+4cBu1QSEPLgtgZxTvpqbRXKy+0weRR6D0rQtVUkAnnriqNnHuYf3QK0JYiwTym2kPnPqPSuefLJG8dy9BdbbiExr8yHIwe1ej6TeCWBJM/eFeaK0kaI6qWYds9q6Dw5qO1ljlUorHAye9KDUNhVafPA9MgG4fWrMcY5rLtLs8bl/EVfE24ZUMa7+dNaHz9SnJaF3GI/l5IHFRmHfkvxVVpJARjNKsspOGORUtN7GPIxlxbQNnKBvesi4063ZiPLQfTmuhjhaYYGR71Zhs0XkjP1oWGlVeqNIYv2S0Zw82gRMd6R/N0yPSsq88OXCudqYUjqRXqnkoOiAU7YCPmANU8svtobwzurTeh4fLZmJ2UgcdcVTlgMh/duD9D0r2y+0e0uQd0QDEY3DgiuK1/wvNaIZ7ZHuIlOSOrAf1rlrYGdL3lqexhs6pVtJ6M5SyH2eIRe+Sa6OzmCABDk4rLt7ZJ2GO3XjOD71ttbQWCLPdX9vDCFy0RXLt9BXDGFSrL3Ua4utSUbvqVbsarqtmthZWtheWUEm+5Eg3s3U4Ckfe96y724sE0yGaS/l02DIQbJfKKtk/IfxrRGr+M5ryJvCHh+1j0MAhjfDyZpG/vBSwwPwrX0631yOWG81RbG2uJV8tYHjMx8w85Ta3C+o68V9JUy5zVOpzO631PBjjI03JtLy7lOwuVW0JEge227nkc5JX1zQ0yGS3J1KG5W7ieSGGKEBgiD1zzzxVu/0bV9N022FrCmoXkjE3MkbiJU44IVs5HbApDJr2rwwWh0SAAAFdS89QsDjowi+8fpmtKeCgm1Wer2HWxKk1Up7GLbTeFbW41KbVPtWj38YUush8hyhHBQDqD0+td14UiDxvfB7hoZgPKSaPayj16nOeuaz4UnNiup+JrKO3u7ElcxSKy3CA9do7HqF5INSTeJbfUQ1jpNtqPnPItuZhbMix5BO7eRjAxXbRw0KPqjz6tVz67/cSa2bv+0JtkDNGNm0Ic7/AKjtWPqNqROZZUmtICvLScDP0q0LTUPsTG4mNveKBseZxIox/EcY4/xq3qTwfaVuI9UVrp4xElujKUYDliF69e+a5PYrEqbqLl3OqFaVDlUNfQxln+ykKrs/y7gf7w9a1LXU96c4/GoNWW/u4luLexR0hGxlWQbsd2H09OpqjqduLAI94wto2GRI/CYx3PY+x5rwMVlkou8FdHfCpSqq07Jm9ujkUluay76LZkoM55rO03WrWQGOK7hnw2A8bhhkdsit1Ss0PqSK8apTnCXLNFcrou62MmOVlx2APNavlRyqrLCG465xVAWUizkqdynsWqxBazuh/wBJMeDjaMGu3DxbWgV5rdM+VzGBKWGMZroNGlSK4jeRQwJ+YHuKwbOYSxhMgnvWlaAIB5nPOQQa9qot0znjJaM7qznR5JEtxIqZygc/Nj8K1YHjEeWj8z5SMA4Irh7S6aOQMjdKtS63PAx2qj8Ywa4J0bvQ7qdZWsb09wCpVi2VztIYqR+IrlmtoLaR5YxKfMBOZJGf145PAzUj6m0y5bgn3qC5umkt1XjgY/Wqpwmriny7kwIkgjOASBioZhiTiPHPWksvmUpISrA1Lc4Vk9ARn3rVJ2szSL0NPS3CkBzwR3q/Ko3RjqM5xWVpBEsTtn5gemO1aSOEI3nJOAPbiuapaKN49zXEYkt1P3T6VKnQA8kDioI38yIbeop6IGYMWJxxxXO3c3jsdBoWstbsIbpvkPCy9fwPpXd2bpcKCp49a8yj2AR8A/WtjTtQmsGDR4aLupPNdFPFNL3kcWJwLqx5obnoy24wBwcVJHbDdyvH0rC0jxDa3ThN+yXujHBrpY5kYAqQ2fTmvXowi0pXPm68atKXLIkjQKgGBgU5uBxTDKo4JwaryT5ACMGOe1dU6kYR0OdRcmTNMqnG4Z+tOV1PIYH8apy2hlGd20/TNV3tp42BQ5/CsFOclexooRelzVByetOIBB4zms6189X/AHinFaAOQK6cLU5naSM6keXYwNW8P208/wBpiQrJj5gpwDWPLCkWXa2E7JxtYDOPxruAOvpWPfWoEsjxuoVvvKTj8qzxuHcKiq0lr2OvDYpuPJMo6dOs8MutzPPAgAU20pVhCFPOAmck5pL/AMR2YvvJSWBWtCJbl7mN0EcRXOUYjBbkcfWont/3en3VlIsdvHcMzozkKwPUtx8xGO9UBCt+l++oXFvqCvN8kUibY8fwqeMY/DmtZY1xsmrNkRoJybb0JofEEuoQM6JC8JfdBIhZScNwSGwRwKguYo719yiS3lzuZo5D9/1GDT7bULA2sE8gg+1zsYjBbneC44CqTjtVWza4kuGNxY3tnycC4VRn6YJrysV9Z9rzN80e+35ndh4Ure6i3ZyXdq0kOo6hJqccpHyTpGNg9toFbmm6npgf7JbkRSsS/lkHn3z0rPljtlt1LLG0pbJLcEDHbjk1SkMZVVSJVccbx1xR/aVWjPV3RLw0K2ysX9OsroPO+q64lwfOLbFEYVY88IeP171evTaSXiRQxwhox5jShBwD2BFc0yR7njW3iknlGNpQfP8AX1/Gm2M2oSLPZSiPT3RimJVG08cMD3HPevR+u/WKWkbJ6GcsM4SvzbDr6G4uJbwaTeTmdQBJbxFP3gz0OenXsQfeuguZ7e605TcyRlrTDT2seyQg7fuOOcVHamx0dVSGIzzGPfNcwqo8wgdWIIyTiue/tS1aSSRdPgsp7py0rxx/NMezHAyxxxk/StZVYYKCju+xPs5V3dKyXUhE17q1wY28KS6PZMN4unaIjP8AuoxOfwqzYyiF3tzN5/OAwBBx71BBpV+bdrk6s32ZWO2J24b2/wDrVkmVYLkMG6nJw22vAzRxqSjLls2erhaLcHFS5kjr4XAOcjpkVcg1CJYgpRcj2rkW1YS3LpawSSoi5ygzjHXmq66mWUGPO088VxUuek720B4T2ujdmfMls7ADBwa0obxlAUk/lWZF8q08Oxr6adNSdzz4S0N+C/KnJPHpU0t3uhkkXgjgVhxNtHzdfarEDEIwLE5rmdNJnRGRoRTM7FVOOKnMhZQFyMVRtmAcGrqEF8ZqZxRrFtmjbsZkVFOCvJqd/nbnnBrOt323AXvir8Z+8e/WueWjOinK+ho6VncykKhbjmtdEiZMkjI9KyLJlfaVOWatmBvLk2SqNpHPrXFV952Oun8I61OCy9uMVozlJEjNsTESOVZc1iRPu80ocHNa8LBWxGSy/wBcVzGidiTO1fnYqA3XFaEUilBjn0NVCBIoVwc1NbL5YCntSlsbRlpYneC3lYPLbxyytjDtgsmPStCz1a/tygtptsanBR0J/rxVFASz7cZ5IqZdyqN45q1iJpWTInRpzVpI6KHxLK3M8LKOm5TuzWvp+o2xK7JUJx91m5/KuIaQBOhNOiVWYHbkj1q45hUhvqcNXLacl7uh6fHeLJgDGfarKMDjFecw391B/q2z7Ma0rXxIwH72IoR3UZr1cPm0GtWeNXymad4HccetAxmsC11+CVfmPP8AtLip31iIA8qR7V6cMfQ3OF4StF2sadxKY1JrA1GV7hHFtCk1wfuq7bR+dRXWsxs53uxjHRVU5rLtrmV5kngNzFGqbWR/XJ6cde9YVMVSm/eenkdFLDyjG7WpatXvIkEF5bwW7DLbFcSAg++BVyzgTKwyCKS3kbOzb3+tUYYxHuZry6u3YDDXAG5R+CipZoIpYP3w+UDnOQPzrn9pB1E4apdzbkvC2zNm2Sz0qQ21tbwwWu3zcpwAxPpVXUpvtMysh+QdOKi0jTYNkaJauYNuQWY4H580xpIDn7Oysm4rlTkAitcfXqyj2izKjTip6O7RSnXk7iT9ahcYYHox461cnDgFo9pcdAxwM1jzWGr2N8kl+tq9rNnaYFIMJ7Kck5+teFLDVKico9D0oVIJ8r0Lq3syxmJJTGAcgoOfxqrq1vHrEDw38UVyrcurpww9wetW7VbZ2JmyOOmOCar3RAOIxz+P9KKdeUI8ty4Rh7S6WpmwQafpFusVlZxRRqhXykj49uKqaZ4ns9Ev5bjUdBu5ZGXEVzZ23ntj+7gdK0Id926Q2cRkld8Bip2L689z7Vrvo4fV7WznWNv3W+V8YU89FHXNelgljItVJK/qTiZ0OVwl17HO3uoWOrSRyWWnXdpEmWVZ0MQJPU7McGs6+hLpuTgAdDXQXdnb2uoyR3PlSxIxwsTAkDsCM5BrK1FdNhuHbT7i7kL9YXXKx+y8Vy43D1qs3Vb26HXgpwhBQpRdn1MnM8LM0EsseR83ltjNVBcvHlQzD61pO21mLRryp4I61jyj584Arkg246nXJK90eGhsYqRR0NQwnPNTZwwr6eTPmYlkdKmi+7VcMM4zU8RBHFYNO5utkWISQasITvz3NUydvJqe3PC/Woka079TR5JWT+6K17YIQMZJPrWSDgAGr1oSAsg6joK5a2h009HqWrVTCx28YPFatxK+xWzzjqayl+bDNwc5q20gaLOetc7SOmLexcsFymdzgseSozW9YzpLKUb7y88VkWBIVsHH0zVw2rxyeZG7B2XGc9q4pRu9zVbF83Sh3XjIOBUqybnXFUPL+4wHmMOvatGCNHVTgqByamWxvHcVZJTM/lgfIwGTkcf1q8jGTBJ4/rUKncnHrmkhJWU4rKd0jQtIo61ZjACg1AqhnO/irOzaUOf1rCTehlN9GPYbVLdsURsnRc5PtQxIbA6UhB2rtHOakyWg5DliCAfwq3brliBnpxVJt6T71HyEc/WrkbMYVdPlf0raEnsY1VpoLKoWRCJMuDnb1NaNjYzZgcXUkzTEgROvypznORVAbTMjSfL6tWhpOpaPpt9cvNqjefNEJFhlkOAgJ+YL254zXtZXR9vJqWx52NlKEFy6stX0C2U4a5ulVpD8qBcjaOpyBnvUMkojZReLsiZsqx5DqOpx9KWTULi7mdzFHHF91Nsm4MvHJGBg1V+by4EYMTCzbWL5yD6+1enP6rCf7t2aOanTquKc9zdPiKwaJ1spDNKi8IEYA/iRWQjHJby4Yix3FIvu5NNM2FwT+HaojMEOWwM9K4MbjpVrXWiLoYWNJ3W5YM+0/MAT6HpTLi+lnhWEgCJOQoJPP40kMmX3YUiklnySNqj6V5ssVKMWovc3dJSkm0Uw4Xr19KRVkuZFW3O64bhVxx+dOlUujBRnNV45rqx/e2riOZe7DeMfSssNVgpJVtvI6pXcXybj5dS1S3srmxudOidDlA9uxTPqTyCPqKyprG2ngZrq5ulkAz8s7g4HbdnNXnuJp1LysGdzuYrwM0zzFjIHlrIO4c5Br1Z5pUqaJ2ithU8MoxbtqxyadpENlDBZzq19KQxd3JOP9o55P1qpc2hW5WFXgmlbgeSeDjpz61HPHbtlWtwkLn50iXt7UxodPtJQdFgmtkCgZb5TkdxWU6lOtC0t7lUqU6Ut90yhcIrXskBkAuE4aNpFBX8zWfcRr5n+sHSuv106bFo9pdL4f0zUL67fMr3CqhBx9/dtJJrnQYFUL5CrtGMbv8BVVsNTopcsr3FQxFSs2pK1j5zt246VZQ7gcjtVKMkN7Vaj7817ko6XPHiTqNp9asQnAqpk1NETt61k9UaxlsWHOUq3ZD5MHms4t2Jq9bSgRkDrWM1Y3jLU1Q4BGR1qyrfKuDgCspJC5XnpV4EmJQp5zzXNVhdXN1O5fHzR/K3QZq5ZqTEpbOcE4/DNUbTGQT0rYVlGF2g5HX0rklKyN1OzL2nqXjJbI3AdParLSugQBXfJ25HaobNwsZOeAatRS/60CON1cbRnIK+4x/WuSW5unZEsMnzMpHA9OtbVqyeUFAIOO/esW0bdcyNswM8cVq24LsJcfKnbsaiV7aG8Zak0fyjJH0pSUaTauQepq20USwBgwZuvWqshBulUDDYyR7VjK9rM1UrkluQfkc5Aq+FRlJYYK9Pes+MASjj61ejB28is0+hnVFZVljxu2ili+RNpOSOlIZRGu1VHrxQjiRgSKpcr6GViVR5nFWFGyMDrgUw4X5otvUcH60sb+YxVsDBwTQrRdzKT5idIEnIR325YAetbWn2cMUAia4kcKjDdIc9O+fas2yuY7OVppFEiKc4H9KtaxdIXVTZ/arZ48tGrbGOQM4ORivayyqqas3a55OLlUcuWK8yCNmEceJo7j5c71PXn/CmsxB5FS28sQhDLb/ZYCgKxuRlB05/L1qNmSTPluj47qQcVNZpzk1sXTk7WaGSrhN2evrTJUEsahZMYPODVmNhHLmVQcdiMio7iRHkLBVQHoAMVzzaaNE3zWsIYhJ8jyOitwSpxip5LNLePImeRccbuaqpMozk9OlNaYuT85x+dQppRcbFOEnK6ZMCMDaM+tJd2+IlckYY9Kihd1kVogrYPORxU+q3u8IpVM9flOcVzOEbOQvfVRRS0MaaNgxKkbaqz59atSNlsg1Xk5Pb8elTFaNnqwVkRMuFDBju7Co23EnczE/XpUoyVbdjg8YqLaWGeoo9ou5ZTvJH8sK0jMqngE5xWbI/zn5iK0bsADBHJ6VmTiAyEqWwfWuqD05nuRJ8ulj58Q5IPpzVqNuM4qkpIOM1biGVr6yemh8xTfMTA5FSxvjjBqHGOhoBI5BrL5GiWu5YYg1Yt3GRVIOcetPWRgcDFZyXMbRaTNe3YYHIrQhbpxwTisW3c7e3FaEErYQcdaxnBvQ6bxRsW5A+U9zWlk70IPFYImYMvAPPeti1kLqpIH61wVKTSKjJXNS3lySCpDNVsfvI9gdhsORtOKzz8jqw5JOOatacSZpu3oK5pU23pY6I1Y21Na3O2Q54GBg1rLKDEPLG3jJGaxV5Vc1oWaCbczk5UgDFcsmludUbN+6WLWQyOxbHl4wOOatLwN569Ae9UJpWjyFxgHHSrts5lTL4yB2rJuLNlGSJYcFzlsVZUkKRuBqi33quEBU3dT71jzx5rETt1HICEzuXJ7YqaFCCW3k57UyAB1ZiOani++BnitU09znnUURCB3z+FPhRTkqCD9akKK33qgi4uiB0zinaPmZ3TRcUAqwyAQOOKn+0yTELIQWC7d2MVXYkAY705fu5711Utfdic8uV6s2GjC6XE0oW4OMGIKMvz0pLqPTplgms41glT5WjjAXPHII9arXcmLKwbahZyQSRTY22ghQBtOBxXqKs4wdPlVmeZGCb5rvcgEvm8GIoQMru4NJ8mfncVLJdSyyBXbIxikWJO6g8968qo4J2Vzvpy93UYVQJuyMVWwpJcA81YkbblQAAM1DAM7s1F0aRmiS3cOrpKsgDDAK4wD61DJGqE87scZxUrAHJqurEuVPTGadas1BRsrFQik+a5Xdefl6VCyhWGTxVyThsDiq12qqeAK5adRSudUKqehDLjbwRVdn/dYHHNPk+70AqJgPKJ74zV+7/VjoTVrlC6O5huNY8rhXIxnHetG8Y4J9KwZ5mWUjg/WumnqtDGpOKV2f/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image showing the posterior end of an adult",
"    <em>",
"     T. trichiura",
"    </em>",
"    , taken during a colonoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichuriasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Trichuriasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Trichuriasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3312=[""].join("\n");
var outline_f3_15_3312=null;
var title_f3_15_3313="Pharyngitis in a patient with PFAPA syndrome";
var content_f3_15_3313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pharyngitis in a patient with periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3313=[""].join("\n");
var outline_f3_15_3313=null;
var title_f3_15_3314="HH and LES pressure on reflux";
var content_f3_15_3314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Interaction of hiatal hernia size and LES pressure on reflux",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Model showing the relationship between hiatal hernia size, lower esophageal sphincter (LES) pressure, and reflux score. The reflux score increased with increasing hernia size and lower LES pressure, both of which were required for marked reflux.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992; 117:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3314=[""].join("\n");
var outline_f3_15_3314=null;
var title_f3_15_3315="Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)";
var content_f3_15_3315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85795\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\">",
"         Prostate gland",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?43/44/44748\">",
"          Choosing treatment for low-risk localized prostate cancer",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/35/24114\">",
"         Patient information: Brachytherapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/3/2099\">",
"         Patient information: Prostate cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/27/32176\">",
"         Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/55/38770\">",
"         Patient information: Prostate cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/39/40565\">",
"         Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H112604895\">",
"      <span class=\"h1\">",
"       What is low-risk localized prostate cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Low-risk localized prostate cancer is prostate cancer that is very slow growing and grows only in the prostate gland (",
"      <a class=\"graphic graphic_figure graphicRef65675 \" href=\"UTD.htm?36/32/37382\">",
"       figure 1",
"      </a>",
"      ). It has not spread outside of the prostate gland.",
"     </p>",
"     <p>",
"      This type of prostate cancer usually grows slowly and does not usually lead to death. Many men with low-risk localized prostate cancer die from other medical problems, such as heart disease, and not from their prostate cancer.",
"     </p>",
"     <p>",
"      But some low-risk localized prostate cancers will become serious and can lead to death if not treated. Unfortunately, doctors can&rsquo;t tell for sure which low-risk localized prostate cancers will never cause any problems and which ones are more serious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112604910\">",
"      <span class=\"h1\">",
"       What are the treatment choices for low-risk localized prostate cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, most men can choose from the following different treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Active surveillance &ndash; Men who choose this do not have treatment for their cancer right away. But their doctor will do exams and tests on a regular basis to check whether the cancer is growing. If and when it does, men then start active treatment. Many men who choose active surveillance end up having treatment for their cancer at some point.",
"       </li>",
"       <li>",
"        Prostatectomy, which is surgery to remove the prostate gland",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells. People can get radiation therapy in 2 different ways:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        In &ldquo;external-beam radiation therapy,&rdquo; the radiation comes from a machine that is outside the body. This involves getting radiation every day for a number of weeks.",
"       </li>",
"       <li>",
"        In &ldquo;brachytherapy,&rdquo; the radiation comes from a source of radiation that is put into the prostate gland. This involves a 1-time treatment.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These are the main treatments for low-risk localized prostate cancer. But some men, especially elderly men with serious medical conditions, might choose none of these. Instead, they might choose &ldquo;watchful waiting.&rdquo; This is different from active surveillance. Watchful waiting involves treating symptoms if and when they happen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112604925\">",
"      <span class=\"h1\">",
"       How do I choose among the different treatments?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, make sure you understand all the facts about your choices (",
"      <a class=\"graphic graphic_table graphicRef85784 \" href=\"UTD.htm?43/44/44748\">",
"       table 1",
"      </a>",
"      ). Ask your doctor any questions you have. Then to help you decide, think about how you feel about these issues:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What the treatment involves",
"       </li>",
"       <li>",
"        Benefits of the treatment &ndash; With active surveillance, men can avoid the side effects from surgery or radiation for as long as possible. With surgery, external-beam radiation therapy, and brachytherapy, the cancer is treated right away before it can grow or spread.",
"       </li>",
"       <li>",
"        Downsides and side effects of the treatment &ndash; Men who choose active surveillance need to be monitored by their doctor for a long time, possibly for the rest of their life. This might include having many biopsies. Another downside of active surveillance is knowing you have cancer and worrying about it. Also, sometimes the cancer starts growing quickly and becomes harder to treat.",
"        <br/>",
"        <br/>",
"        Surgery, external-beam radiation therapy, and brachytherapy can all cause trouble with sex. This includes trouble getting or keeping an erection. With surgery, this problem usually happens right away. With external-beam radiation therapy and brachytherapy, this problem can happen later on.",
"        <br/>",
"        <br/>",
"        Surgery can cause incontinence, which is when people leak urine. Also, side effects such as pain, infection, and bleeding can happen with any type of surgery.",
"        <br/>",
"        <br/>",
"        External-beam radiation therapy and brachytherapy have short-term and long-term side effects. Short-term, they can cause frequent bowel movements and other bowel problems. They can also cause problems with urination, including the need to urinate often or pain with urination. Long-term, these treatments sometimes make men leak urine, but this is less common.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How the treatment could affect your sex life &ndash; Active surveillance doesn&rsquo;t usually affect a man&rsquo;s sex life. But surgery, external-beam radiation therapy, and brachytherapy can cause trouble getting or keeping an erection. If you have problems with these, there are treatments (medicines or devices) that might be able to help.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your treatment might also depend on your age and general health. For example, younger men in good health often choose surgery. Older men, especially those with other medical conditions, might choose active surveillance.",
"     </p>",
"     <p>",
"      Also, people with certain medical conditions cannot have some treatments. For instance, men with long-term diarrhea usually can&rsquo;t have external-beam radiation therapy or brachytherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112604940\">",
"      <span class=\"h1\">",
"       What are the chances my cancer will come back after surgery, external-beam radiation therapy, or brachytherapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After all of these treatments, there is a very low chance that your cancer will come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112604955\">",
"      <span class=\"h1\">",
"       How do I work with my doctor to make a decision?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To make a decision, let your doctor know how you feel about the different treatments and whether there is something specific that worries you. Then listen to what your doctor has to say about his or her experiences with men who had situations similar to yours. Together, you can decide which treatment is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112604970\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/3/2099?source=see_link\">",
"       Patient information: Prostate cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/27/32176?source=see_link\">",
"       Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=see_link\">",
"       Patient information: Brachytherapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"       Patient information: Prostate cancer screening (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/15/3315?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85795 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3315=[""].join("\n");
var outline_f3_15_3315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112604895\">",
"      What is low-risk localized prostate cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112604910\">",
"      What are the treatment choices for low-risk localized prostate cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112604925\">",
"      How do I choose among the different treatments?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112604940\">",
"      What are the chances my cancer will come back after surgery, external-beam radiation therapy, or brachytherapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112604955\">",
"      How do I work with my doctor to make a decision?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112604970\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\">",
"      Prostate gland",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?43/44/44748\">",
"       Choosing treatment for low-risk localized prostate cancer",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/3/2099?source=related_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=related_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/27/32176?source=related_link\">",
"      Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3316="Anthralin: Patient drug information";
var content_f3_15_3316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Anthralin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     see \"Anthralin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dritho-Creme&reg;;",
"     </li>",
"     <li>",
"      Dritho-Scalp&reg;;",
"     </li>",
"     <li>",
"      Zithranol&reg;-RR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anthraforte&reg;;",
"     </li>",
"     <li>",
"      Anthranol&reg;;",
"     </li>",
"     <li>",
"      Anthrascalp&reg;;",
"     </li>",
"     <li>",
"      Micanol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to anthralin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fabric, flooring, painted surfaces, marble, granite, vinyl, and enamel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean shower or tub right away after use to avoid staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a rubber glove to put on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid putting on healthy skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on the skin for as long as the doctor told you to, then wash off.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11165 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3316=[""].join("\n");
var outline_f3_15_3316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135607\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135608\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014568\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014567\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014572\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014573\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014575\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014570\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014571\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014576\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014577\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=related_link\">",
"      Anthralin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3317="Telbivudine: Drug information";
var content_f3_15_3317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telbivudine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/13/20693?source=see_link\">",
"    see \"Telbivudine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3424967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tyzeka&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4414326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sebivo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3424971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3425005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Chronic hepatitis B:",
"     </b>",
"     Oral: 600 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Treatment duration  (AASLD practice guidelines [Lok, 2009]):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy should either receive additional treatment or be switched to an alternative therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3425004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Chronic hepatitis B:",
"     </b>",
"     Oral: Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3425006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 600 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (not requiring dialysis): 600 mg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     End-stage renal disease: 600 mg every 96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Administer after dialysis session",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3425007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3425014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tyzeka&reg;: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3424969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F7884063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tyzeka&reg; oral solution: FDA approved April 2009; anticipated availability is currently undetermined",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135934.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135934.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3425009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3424972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis B with evidence of viral replication and either persistent transaminase elevations or histologically-active disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3424982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: CPK increased (79%; grades 3/4: 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (10%), dizziness (4%), fever (4%), insomnia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (4%), pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Lipase increased (grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (3% to 6%), diarrhea (6%), nausea (5%), abdominal distension (3%), dyspepsia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (grades 3/4: 5% to 7%), AST increased (grades 3/4: 6%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4%), back pain (4%), myalgia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (6%), pharyngolaryngeal pain (5%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     &lt;1% (Limited to important or life-threatening): Amylase increased, bilirubin increased,  hepatomegaly, hypoesthesia, lactic acidosis, paresthesia, peripheral neuropathy, rhabdomyolysis, steatosis, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3424977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use with peginterferon alfa-2a",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to telbivudine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3424978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	 Myopathy: Use has been associated with myopathy (unexplained muscle aches and/or muscle weakness in conjunction with serum creatine kinase increases) several weeks to months after initiation of telbivudine; interrupt therapy if myopathy is suspected and discontinue therapy if myopathy is diagnosed. Patients taking concomitant medications associated with myopathy should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peripheral neuropathy: May occur alone or in combination with pegylated interferon alfa-2a (concurrent use is contraindicated) or possibly other interferons. Symptoms have been observed within 3 months after initiation of therapy. Interrupt treatment for suspected peripheral neuropathy and discontinue if confirmed; symptoms may be reversible with discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation.",
"     </b>",
"     Monitor liver function several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human immunodeficiency virus: Telbivudine does not exhibit any clinically-relevant activity against HIV type 1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use caution in patients with moderate-to-severe renal dysfunction and end stage renal disease (ESRD); dosing adjustment required (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; African-American or Hispanic patients: Safety and efficacy have not been established in Black/African-American or Hispanic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Coinfections: Safety and efficacy have not been studied in patients coinfected with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Liver transplant recipients: Safety and efficacy in liver transplant patients have not been established; monitor renal function in patients receiving concurrent therapy of cyclosporine or tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate Use: Not recommended as first-line therapy of chronic HBV due to high rate of resistance; use may be appropriate in short-term treatment of acute HBV (Lok, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Resistance: Cross-resistance among hepatitis B antivirals may develop; use caution in patients failing previous lamivudine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3424988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferon Alfa-2b: May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2a: May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3424990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Should be avoided in hepatitis B infection due to potential hepatic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Does not have a significant effect on telbivudine absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3424973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3424974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Health professionals are encouraged to contact the antiretroviral pregnancy registry to monitor outcomes of pregnant women exposed to antiretroviral medications (1-800-258-4263).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3424976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if telbivudine is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3425008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tyzeka Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (30): $1064.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3425011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     LFTs (eg, AST and ALT) periodically during therapy and for several months following discontinuation of therapy; renal function prior to initiation and periodically during treatment; signs and symptoms of peripheral neuropathy (eg, weakness, paresthesia, leg pain) or myopathy (eg, unexplained muscle pain, tenderness or weakness); serum creatine kinase; HBV DNA (every 3-6 months during therapy); HBeAg and anti-HBe signs/symptoms of HBV relapse/exacerbation after discontinuation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4414438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sebivo (AR, AT, AU, BR, CH, CL, CZ, DE, DK, EE, FR, GB, GR, HK, ID, IL, IN, IT, KP, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3424993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Telbivudine, a synthetic thymidine nucleoside analogue (L-enantiomer of thymidine), is intracellularly phosphorylated to the active triphosphate form, which competes with the natural substrate, thymidine 5'-triphosphate, to inhibit hepatitis B viral DNA polymerase; enzyme inhibition blocks reverse transcriptase activity thereby reducing viral DNA replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3424995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &gt; total body water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: No metabolites detected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 40-49 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~42% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kim JW, Park SH, Louie SG, &ldquo;Telbivudine: A Novel Nucleoside Analog for Chronic Hepatitis B,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(3):472-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/15/3317/abstract-text/16507625/pubmed\" id=\"16507625\" target=\"_blank\">",
"        16507625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;Chronic Hepatitis B: Update 2009,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(3):661-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/15/3317/abstract-text/19714720/pubmed\" id=\"19714720\" target=\"_blank\">",
"        19714720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Qi X, Sabagal A, et al, &ldquo;Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues Against Lamivudine-Resistant HBV,&rdquo;",
"      <i>",
"       Antivir Ther",
"      </i>",
"      , 2005, 10(5):625-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/15/3317/abstract-text/16152756/pubmed\" id=\"16152756\" target=\"_blank\">",
"        16152756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9488 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3317=[""].join("\n");
var outline_f3_15_3317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709043\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424967\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4414326\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424971\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425005\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425004\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425006\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425007\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425014\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424969\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7884063\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874995\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425009\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424972\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424982\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424977\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424978\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300109\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424988\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424990\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424973\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424974\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424976\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916862\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425008\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370393\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3425011\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4414438\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3424995\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/13/20693?source=related_link\">",
"      Telbivudine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3318="Arteriovenous fistula recirculation in hemodialysis";
var content_f3_15_3318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arteriovenous fistula recirculation in hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Michael Berkoben, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Peter J Blankestijn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3318/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/15/3318/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of hemodialysis is defined by the dialysis prescription. This prescription includes the duration of treatment, dialysate flow, blood flow, and the specific dialyzer. However, many patients are underdialyzed due, in part, to problems with hemodialysis access recirculation, resulting in dialysis delivery being less than that prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=see_link\">",
"     \"Prescribed versus delivered dialysis: Importance of dialysis time\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One setting in which the presence of significant recirculation should be suspected is when there is an inadequate reduction in the postdialysis blood urea nitrogen (BUN), which should be",
"    <strong>",
"     less than 40 percent",
"    </strong>",
"    of the predialysis value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link&amp;anchor=H6#H6\">",
"     \"Kt/V and the adequacy of hemodialysis\", section on 'Urea reduction ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodialysis access recirculation occurs when dialyzed blood returning through the venous needle reenters the extracorporeal circuit through the arterial needle, rather than returning to the systemic circulation. It is important to measure hemodialysis access recirculation for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reentry of dialyzed blood into the extracorporeal circuit reduces solute concentration gradients across the dialysis membrane by mixing already dialyzed with undialyzed blood. As a result, the efficiency of dialysis is reduced. High degrees of recirculation can lead to a significant discrepancy between the amount of hemodialysis prescribed (prescribed",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      urea) and the amount of hemodialysis delivered (delivered",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      urea). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=see_link\">",
"       \"Prescribed versus delivered dialysis: Importance of dialysis time\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High degrees of access recirculation indicate the presence of access stenoses, the most common cause of access thrombosis. Prospective identification and treatment of access stenoses improves long-term access patency rates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"       \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RECIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access recirculation occurs in conditions of low access flow. The most common cause is the presence of high-grade venous stenoses, which obstruct venous outflow, leading to backflow into the arterial needle.",
"   </p>",
"   <p>",
"    Less common causes are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Access recirculation can be induced by inadequate arterial inflow. In this setting, backflow from the venous limb of the access is necessary to support the extracorporeal blood flow rate set by the blood pump.",
"     </li>",
"     <li>",
"      Access recirculation can result from improper needle placement. Close proximity of the needles will increase the reentry of dialyzed blood into the arterial needle. In some centers, misplacement of needles is a common source of recirculation, even after such placement had been previously recognized [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of access recirculation should directly correlate with compromised access blood flow, as low blood flow is a sensitive marker of stenoses and access pathology. To study this correlation, brachial artery blood flow assessed via Doppler ultrasound and used as a surrogate for access flow was compared with measurements of recirculation among 77 chronic hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/3\">",
"     3",
"    </a>",
"    ]. Only patients in whom access flow was less than the dialyzer blood flow had evidence of recirculation.",
"   </p>",
"   <p>",
"    When hemodialysis catheters are unable to achieve adequate blood flow (greater than 300",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    a common temporary strategy to increase flow is to reverse the line position (in which blood is withdrawn from the venous port and returned via the arterial port). A large amount of the literature suggests that this maneuver significantly increases arteriovenous fistula recirculation (5 to approximately 15 percent or even higher) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this, it is unclear whether attained improved blood flow with reversal improves overall clearance in dysfunctional catheters. This was evaluated in one study of 14 patients with dysfunctional catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/4\">",
"     4",
"    </a>",
"    ]. Although line reversal markedly increased access recirculation (zero to 25 percent), the enhanced blood flow was associated with a significant increase in the mean urea clearance (128",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at a flow of 200",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    to 157",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at maximal blood flow). Thus, overall clearance was increased.",
"   </p>",
"   <p>",
"    Current guidelines suggest, however, that poorly functioning catheters should undergo prompt evaluation and proper treatment to ensure adequate blood flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CALCULATION OF RECIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of access recirculation for urea can be calculated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Percent recirculation &nbsp; = &nbsp; ([P &nbsp;- &nbsp;A] &nbsp;&divide; &nbsp;[P &nbsp;- &nbsp;V]) &nbsp;x &nbsp;100",
"   </p>",
"   <p>",
"    where P, A, and V refer to the urea concentrations in the peripheral blood, predialyzer arterial line, and postdialyzer venous circuit, respectively. The blood samples from the arterial line, venous line, and peripheral blood are obtained simultaneously.",
"   </p>",
"   <p>",
"    If there were no recirculation, the peripheral (systemic) BUN (P) would be equal to the BUN in the blood entering the access (A) and the above formula would have a value of zero. On the other hand, access recirculation exists whenever the BUN in the arterial line blood is lower than that in the peripheral sample, indicating reentry of dialyzed blood into the arterial line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PITFALLS IN ESTIMATING ACCESS RECIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main source of error in the determination of access recirculation lies with the determination of the systemic urea concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"     1",
"    </a>",
"    ]. This value is assumed to be equal to the urea concentration in blood entering the hemodialysis access if there is no recirculation. However, the BUN obtained from a peripheral vein in the contralateral arm is often higher than the BUN in the blood entering the access, even in the absence of recirculation. Two factors contribute to this problem: arteriovenous disequilibrium (also called cardiopulmonary recirculation) and venovenous disequilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arteriovenous disequilibrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialyzed blood (with a low urea concentration) returns to the central veins and dilutes the blood returning from the systemic circulation, which has a high urea concentration. The net effect is that the urea concentration in central venous blood, and therefore in blood leaving the left heart and entering the hemodialysis access, is lower than the urea concentration in peripheral venous blood. Thus, use of the peripheral vein BUN in the recirculation formula will overestimate access recirculation. The degree of arteriovenous disequilibrium rises when the degree of dilution of central venous blood by dialyzed blood is enhanced. This can occur in three settings: with increasing extraction of urea by the dialyzer; or with increasing extracorporeal blood flow rate or decreasing cardiac output, either of which makes the access flow a higher fraction of total cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Venovenous disequilibrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venovenous disequilibrium is a second mechanism that can account for different urea concentrations in peripheral venous blood and blood entering the access [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"     1",
"    </a>",
"    ]. Perfusion of the arm contralateral to the hemodialysis access is low during hemodialysis; as a result, urea removal in that limb is diminished in comparison to well-perfused compartments. Thus, the urea concentration in the veins of the contralateral arm is higher than in central venous blood or blood entering the fistula. This difference increases with time. In one study of 12 patients, for example, the venous BUN the contralateral arm exceeded the BUN in arterial blood of the ipsilateral arm by 10 percent after five minutes of hemodialysis and by",
"    <strong>",
"     36 percent",
"    </strong>",
"    after two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     METHODS OF SAMPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sampling peripheral arterial blood eliminates the effects of both arteriovenous and venovenous disequilibrium and permits the most accurate determination of access recirculation. Unfortunately, arterial puncture during hemodialysis is not practical.",
"   </p>",
"   <p>",
"    The peripheral sample has traditionally been obtained from a peripheral vein in the contralateral arm (\"three-needle\" method). This method should",
"    <strong>",
"     no longer",
"    </strong>",
"    be utilized due to its unpredictable manner, requirement for additional venipuncture, and overestimation of access recirculation (see below).",
"   </p>",
"   <p>",
"    The method chosen should be based upon the",
"    <span class=\"nowrap\">",
"     expertise/organization",
"    </span>",
"    infrastructure of the dialysis staff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Two-needle techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preferred alternatives to the peripheral vein or three-needle method include the stop blood flow technique and the low blood flow technique, both of which directly measure the concentration of blood entering the arterial limb (P in the above formula) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"     1",
"    </a>",
"    ]. In the former, the systemic BUN is measured in blood obtained from the arterial needle after blood flow has been stopped. In latter, the systemic BUN is measured in blood obtained from the arterial needle after blood flow has been reduced to 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    These \"two-needle\" techniques (as opposed to the use of three needles if the peripheral vein is punctured) permit accurate determination of the BUN concentration in blood entering the access.",
"   </p>",
"   <p>",
"    Sherman has concluded that these two techniques yield equivalent results, but that the low blood flow technique is preferred because of greater ease of performance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/10\">",
"     10",
"    </a>",
"    ]. Both techniques are presumably more accurate than the peripheral vein method for the determination of access recirculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonurea-based techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, an accurate assessment of access fistula recirculation can be made by ultrasound dilution technique, conductivity, or potassium-based dilutional method [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Needle placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, proper placement of the hemodialysis needles is important to minimize access recirculation. Placing the hemodialysis needles too close together will increase reentry of dialyzed blood into the arterial needle. We generally try to keep the arterial and venous needles as far apart as possible; the needles point in opposite directions, which will further minimize the likelihood of contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Timing of blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate timing of blood sampling is essential for accurate determination of access recirculation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regardless of the method used, recirculation studies should be performed within",
"      <strong>",
"       30 minutes",
"      </strong>",
"      of the initiation of hemodialysis before ultrafiltration and subsequent alterations in cardiac output, blood pressure, and access blood flow are significant and, if the peripheral vein method is used, before the effects of venovenous disequilibrium are significant [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When the low or stop blood flow technique is used, it is essential to obtain the systemic sample from the arterial limb",
"      <strong>",
"       15 to 30 seconds",
"      </strong>",
"      after the stoppage or reduction of blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"       1",
"      </a>",
"      ]. If obtained later, there will dissipation of arteriovenous disequilibrium, since central venous blood is no longer being diluted with dialyzed blood. As a result, the BUN in the \"systemic\" sample will be higher than the level that existed during dialysis, leading to overestimation of access recirculation. If obtained earlier, dialyzed blood within the access will be included in the \"systemic\" sample. This will reduce the BUN below the level occurring during dialysis, resulting in underestimation of access recirculation.",
"     </li>",
"     <li>",
"      Urea recirculation should be determined at a standard extracorporeal blood flow rate for obtaining systemic arterial sample. In the normal access, the percent recirculation is zero (when determined by the saline dilution method described below) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/14\">",
"       14",
"      </a>",
"      ] or low (when determined by two-needle methods) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/10\">",
"       10",
"      </a>",
"      ] and is not influenced by the extracorporeal blood flow rate. If, however, access blood flow is impaired (due, for example, to venous stenosis), access recirculation may be necessary to support the extracorporeal blood flow rate demanded by the blood pump. In this setting, access recirculation rises as the blood flow rate is increased [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Low blood flow technique protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following standard protocol for performing the low blood flow technique summarizes these issues [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Turn off ultrafiltration approximately 30 minutes after the initiation of hemodialysis.",
"     </li>",
"     <li>",
"      Obtain arterial and venous line samples.",
"     </li>",
"     <li>",
"      Reduce access blood flow to 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      Obtain the systemic blood sample from the arterial blood line after sufficient time has passed to clear 150 percent of the volume between the arterial needle and the sampling point but no later than 30 seconds after the reduction of access flow to 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     K/DOQI guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Kidney",
"    <span class=\"nowrap\">",
"     Foundation/Dialysis",
"    </span>",
"    Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (NKF/DOQI",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     K/DOQI)",
"    </span>",
"    published guidelines in 2006 concerning the preferred methods of measuring access recirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/15\">",
"     15",
"    </a>",
"    ]. The recommendation is to measure recirculation using a nonurea-based dilutional method, which requires special equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE OF ACCESS RECIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access stenosis is likely if the percent recirculation exceeds a threshold value, assuming that low cardiac output or suboptimal needle placement is not a problem. The previous threshold value of urea recirculation, greater than 15 to 20 percent, was based upon studies utilizing the traditional peripheral vein-three needle method. Current threshold values for the evaluation of possible stenosis are based upon more accurate methods [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines state that further investigation is required with values greater than 10 percent, as assessed by urea-based recirculation measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/15\">",
"     15",
"    </a>",
"    ]. For surveillance purposes in fistulas, they believed that recirculation, if used, should only have a minor role. They also stated that recirculation is a relatively late predictor of fistula access stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis\"",
"    </a>",
"    .) Although intra-access flow, static venous pressure measurements, and ultrasonography are suggested as methods for access surveillance (especially in grafts) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3318/abstract/15\">",
"     15",
"    </a>",
"    ], periodic recirculation assessments can be done in the absence of appropriate equipment.",
"   </p>",
"   <p>",
"    Recirculation that is greater than 10 percent should be considered abnormal and should indicate that access blood flow approaches the level of blood flow through the extracorporeal circuit, which is typically approximately 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Because of the great likelihood of venous stenosis and the associated increased risk of thrombosis, fistulography should be performed.",
"   </p>",
"   <p>",
"    Significant recirculation should also be suspected when there is a significant discrepancy between the prescribed and delivered",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    urea or when there is an inadequate urea reduction, as shown by the postdialysis BUN exceeding 40 percent of the predialysis BUN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodialysis access recirculation occurs when dialyzed blood returning through the venous needle reenters the extracorporeal circuit through the arterial needle, rather than returning to the systemic circulation. Recirculation reduces the efficiency of dialysis and may indicate the presence of access stenoses, the most common cause of access thrombosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of access recirculation is the presence of high-grade venous stenoses, which obstruct venous outflow. Other causes include inadequate arterial inflow and improper needle placement. With catheters, a cause of recirculation is reversing the line position. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of recirculation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degree of access recirculation for urea can be calculated from the following formula:",
"      <br/>",
"      <br/>",
"      &nbsp;Percent recirculation &nbsp; = &nbsp; ([P &nbsp;- &nbsp;A] &nbsp;&divide; &nbsp;[P &nbsp;- &nbsp;V]) &nbsp;x &nbsp;100",
"      <br/>",
"      <br/>",
"      where P, A, and V refer to the urea concentrations in the peripheral blood, predialyzer arterial line, and postdialyzer venous circuit, respectively. The main source of error lies with the determination of the systemic urea concentration, with arteriovenous disequilibrium and venovenous disequilibrium principally contributing to this error. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Calculation of recirculation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pitfalls in estimating access recirculation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are multiple of methods of sampling to best assess the presence of hemodialysis access recirculation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Methods of sampling'",
"      </a>",
"      above.) The method chosen is based upon the expertise and organizational infrastructure of the dialysis staff.",
"     </li>",
"     <li>",
"      Recirculation that is greater than 10 percent should be considered abnormal. Fistulography should be performed in these settings. Significant recirculation should also be suspected when there is a significant discrepancy between the prescribed and delivered",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      urea or when there is an inadequate urea reduction, as shown by the postdialysis BUN exceeding 40 percent of the predialysis BUN. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical significance of access recirculation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/1\">",
"      Sherman RA. The measurement of dialysis access recirculation. Am J Kidney Dis 1993; 22:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/2\">",
"      Schneditz D. Recirculation, a seemingly simple concept. Nephrol Dial Transplant 1998; 13:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/3\">",
"      Besarab A, Sherman R. The relationship of recirculation to access blood flow. Am J Kidney Dis 1997; 29:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/4\">",
"      Carson RC, Kiaii M, MacRae JM. Urea clearance in dysfunctional catheters is improved by reversing the line position despite increased access recirculation. Am J Kidney Dis 2005; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/5\">",
"      Atherikul K, Schwab SJ, Conlon PJ. Adequacy of haemodialysis with cuffed central-vein catheters. Nephrol Dial Transplant 1998; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/6\">",
"      Depner TA, Krivitski NM, MacGibbon D. Hemodialysis access recirculation measured by ultrasound dilution. ASAIO J 1995; 41:M749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/7\">",
"      Sen&eacute;cal L, Saint-Sauveur E, Leblanc M. Blood flow and recirculation rates in tunneled hemodialysis catheters. ASAIO J 2004; 50:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/8\">",
"      Pannu N, Jhangri GS, Tonelli M. Optimizing dialysis delivery in tunneled dialysis catheters. ASAIO J 2006; 52:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/9\">",
"      Depner TA, Rizwan S, Cheer AY, et al. High venous urea concentrations in the opposite arm. A consequence of hemodialysis-induced compartment disequilibrium. ASAIO Trans 1991; 37:M141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/10\">",
"      Sherman RA, Matera JJ, Novik L, Cody RP. Recirculation reassessed: the impact of blood flow rate and the low-flow method reevaluated. Am J Kidney Dis 1994; 23:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/11\">",
"      Brancaccio D, Tessitore N, Carpani P, et al. Potassium-based dilutional method to measure hemodialysis access recirculation. Int J Artif Organs 2001; 24:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/12\">",
"      Bosc JY, LeBlanc M, Garred LJ, et al. Direct determination of blood recirculation rate in hemodialysis by a conductivity method. ASAIO J 1998; 44:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/13\">",
"      Alloatti S, Molino A, Bonfant G, et al. Measurement of vascular access recirculation unaffected by cardiopulmonary recirculation: evaluation of an ultrasound method. Nephron 1999; 81:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/14\">",
"      Tattersall JE, Farrington K, Raniga PD, et al. Haemodialysis recirculation detected by the three-sample method is an artefact. Nephrol Dial Transplant 1993; 8:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3318/abstract/15\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1907 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3318=[""].join("\n");
var outline_f3_15_3318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF RECIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CALCULATION OF RECIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PITFALLS IN ESTIMATING ACCESS RECIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arteriovenous disequilibrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Venovenous disequilibrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      METHODS OF SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Two-needle techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonurea-based techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Needle placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Timing of blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Low blood flow technique protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      K/DOQI guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL SIGNIFICANCE OF ACCESS RECIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1144?source=related_link\">",
"      Prescribed versus delivered dialysis: Importance of dialysis time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3319="Management of severe ulcerative colitis";
var content_f3_15_3319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Management of severe ulcerative colitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Richard J Farrell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3319/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/15/3319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum, and may extend in a proximal and continuous fashion to involve other portions of the colon.",
"   </p>",
"   <p>",
"    Patients with severe presentations of ulcerative colitis are generally categorized as having either severe or fulminant ulcerative colitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a severe ulcerative colitis have frequent loose bloody stools (&ge;6 per day) with severe cramps and evidence of systemic toxicity as demonstrated by a fever (temperature &ge;37.5&deg;C), tachycardia (heart rate [HR] &ge;90",
"      <span class=\"nowrap\">",
"       beats/minute),",
"      </span>",
"      anemia (hemoglobin &lt;10.5",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      or an elevated erythrocyte sedimentation rate (ESR) (&ge;30",
"      <span class=\"nowrap\">",
"       mm/hour).",
"      </span>",
"      Patients may have rapid weight loss.",
"     </li>",
"     <li>",
"      Fulminant colitis refers to a subgroup of patients with severe ulcerative colitis who have more than 10 stools per day, continuous bleeding, abdominal pain, distension, and acute, severe toxic symptoms including fever and anorexia. Such patients are at risk of progressing to toxic megacolon and bowel perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the management of severe and fulminant ulcerative colitis. The management of mild to moderate colitis, steroid-refractory and steroid-dependant ulcerative colitis, and toxic megacolon are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133540027\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with symptoms suggestive of ulcerative colitis, an assessment of disease severity is important in guiding management. It is also important to exclude alternative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    comorbid conditions as a cause for their symptoms even when the diagnosis of ulcerative colitis has been previously established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H1226801754#H1226801754\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Assessment of clinical severity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H350978455#H350978455\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation should consist of laboratory studies including blood counts, liver tests, measurement of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), stool studies to rule out an infectious colitis, and a limited evaluation of the colon with flexible sigmoidoscopy to confirm the presence, severity, and extent of inflammation, and to obtain biopsies to exclude the presence of an infection (eg, cytomegalovirus). A full colonoscopy should be avoided in hospitalized patients with severe colitis because of the potential to precipitate toxic megacolon. Because of the severity of symptoms, treatment should proceed pending the results of investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H350978455#H350978455\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe or fulminant ulcerative colitis should also undergo plain abdominal radiography both at presentation and at any time there is clinical deterioration to determine if there is colonic dilation (diameter &ge;5.5 cm) or toxic megacolon (diameter &ge;6 cm or cecum &gt;9 cm and systemic toxicity). The management of toxic megacolon is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link&amp;anchor=H8#H8\">",
"     \"Toxic megacolon\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link&amp;anchor=H12#H12\">",
"     \"Toxic megacolon\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133536041\">",
"    <span class=\"h1\">",
"     TREATMENT OF SEVERE ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a severe ulcerative colitis have frequent loose bloody stools (&ge;6 per day) with severe cramps and evidence of systemic toxicity as demonstrated by a fever (temperature &ge;37.5&deg;C), tachycardia (heart rate [HR] &ge;90",
"    <span class=\"nowrap\">",
"     beats/minute),",
"    </span>",
"    anemia (hemoglobin &lt;10.5",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    or an elevated erythrocyte sedimentation rate (ESR) (&ge;30",
"    <span class=\"nowrap\">",
"     mm/hour).",
"    </span>",
"    Patients may have rapid weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133540232\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe ulcerative colitis should be treated with oral glucocorticoids and combination therapy with high dose oral 5-aminosalicylic acid (5-ASA) (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    4.8",
"    <span class=\"nowrap\">",
"     grams/day),",
"    </span>",
"    5-ASA or steroid suppository, and 5-ASA, steroid enema, or foam (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H100504367#H100504367\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Initial approach'",
"    </a>",
"    ). Some patients should also receive antibiotics. Initiation of oral glucocorticoids should not be delayed until the results of stool studies and cultures are available [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1133540027\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although there are no randomized controlled trials to support the use of oral 5-ASA medications in severe colitis, clinical experience along with their documented benefit in patients with milder symptoms suggests that oral 5-ASA medications may be a helpful adjunct in the management of patients with severe colitis. However, in rare cases, some 5-ASA medications have been found to cause exacerbations of colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/2\">",
"     2",
"    </a>",
"    ]. If an ulcerative colitis flare coincides with a recent increase in dose or addition of an oral 5-ASA medication, oral 5-ASA medications should be discontinued.",
"   </p>",
"   <p>",
"    No randomized controlled trials have demonstrated a benefit to topical therapy in patients with severe ulcerative colitis. However, we have found that steroid",
"    <span class=\"nowrap\">",
"     enemas/foam",
"    </span>",
"    and suppositories or 5-ASA enemas twice daily may be helpful in relieving rectal symptoms of tenesmus and urgency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H113301576#H113301576\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Ulcerative proctitis or proctosigmoiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticholinergic, antidiarrheal agents, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid drugs should be discontinued in patients with severe colitis due to the risk of precipitating toxic megacolon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend intravenous antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) in patients with severe colitis and high grade fever, leukocytosis with extreme numbers of immature neutrophils (band form count greater than",
"    <span class=\"nowrap\">",
"     700/microL),",
"    </span>",
"    and peritoneal signs or megacolon. There is no role of antibiotics in patients with severe colitis without signs of systemic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bowel rest is not recommended in patients with severe ulcerative colitis in the absence of fulminant disease (see",
"    <a class=\"local\" href=\"#H1133536048\">",
"     'Treatment of fulminant ulcerative colitis'",
"    </a>",
"    below). Although bowel rest can help reduce stool volume, it has no established benefit on disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nutritional support should be considered in patients who are malnourished. In such cases, enteral nutrition is preferred, as it is associated with significantly fewer complications than parenteral nutrition and does not deprive the colon of short chain fatty acids needed for the metabolism and repair of colon epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H642204851#H642204851\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Nutritional assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H3593887#H3593887\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Dietary interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239353307\">",
"    <span class=\"h2\">",
"     Subsequent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who continue to have symptoms despite optimal doses of oral steroids, high dose oral 5-ASA, and topical 5-ASA or steroids medications should be hospitalized for further management that includes intravenous fluids, electrolyte repletion, and intravenous steroids.",
"   </p>",
"   <p>",
"    Regimens for intravenous steroids include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (30 mg IV every 12 hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (16 to 20 mg IV every eight hours), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (100 mg IV every eight hours). Prednisolone or methylprednisolone are preferred because they are associated with less sodium-retention and potassium-wasting. A systematic review of 32 trials and cohort studies of intravenous glucocorticoids included 1991 patients with acute severe colitis between 1974 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/9\">",
"     9",
"    </a>",
"    ]. The overall response rate (both partial and complete) to glucocorticoids was 67 percent; 27 percent of patients required a colectomy. Continuous infusions of intravenous glucocorticoids are not safer or more effective than bolus injection in achieving clinical remission in patients with severe ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest broad-spectrum antibiotics in patients who improve but do not fully respond to glucocorticoids, and who continue to run low grade fevers with evidence of band forms in their differential. We typically use a regimen of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in this setting.",
"   </p>",
"   <p>",
"    Pharmacologic venous thromboembolism prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) should be administered to reduce the risk of thromboembolism in patients hospitalized with severe ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Studies have demonstrated an increased risk of venous thromboembolism and pulmonary embolism in patients with inflammatory bowel disease in both population-based and hospital-based cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Prevention of VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=see_link&amp;anchor=H272016037#H272016037\">",
"     \"Pulmonary complications of inflammatory bowel disease\", section on 'Prophylaxis for venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have no meaningful clinical response to intravenous glucocorticoids within 7 to 10 days are considered steroid refractory and should either be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or an anti-tumor necrosis factor (anti-TNF) agent. An approach to patients with steroid-refractory ulcerative colitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324559250\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who respond, intravenous glucocorticoids should be converted to equivalent dose of oral glucocorticoids in three to five days. Oral glucocorticoids should be tapered after the patient has been stable for two to four weeks. Oral glucocorticoids should be tapered over eight weeks by decreasing the dose by 5 to 10 mg every week until a daily dose of 20 mg is reached, and then by 2.5 mg every week [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/17\">",
"     17",
"    </a>",
"    ]. Rectal",
"    <span class=\"nowrap\">",
"     5-ASA/steroids",
"    </span>",
"    can be gradually tapered over two to four months. Oral 5-ASA medications should be continued at the same dose as maintenance therapy.",
"   </p>",
"   <p>",
"    Patients are considered to have steroid dependent ulcerative colitis if glucocorticoids cannot be tapered to less than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    within three months of starting glucocorticoids without recurrent disease, or if relapse occurs within three months of stopping glucocorticoids. Patients with steroid-dependant ulcerative colitis, patients with severe ulcerative colitis with &gt;2 relapses requiring glucocorticoids in 12 months despite optimal doses of oral 5-ASA medication, or patients who cannot tolerate 5-ASA medications should be treated with 6-mercaptopurine",
"    <span class=\"nowrap\">",
"     (6-MP)/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"    </span>",
"    (AZA) or an anti-TNF agent for maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]. An approach to patients with steroid-dependant ulcerative colitis and the administration, safety, and monitoring of AZA and 6-MP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H526355188#H526355188\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Steroid-dependent ulcerative colitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133536048\">",
"    <span class=\"h1\">",
"     TREATMENT OF FULMINANT ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fulminant colitis refers to a subgroup of patients with severe ulcerative colitis who have more than 10 stools per day, continuous bleeding, abdominal pain, distension, and acute, severe toxic symptoms including fever and anorexia. Such patients are at risk of progressing to toxic megacolon and bowel perforation. The treatment of fulminant colitis is the same regardless of the extent of colonic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133536814\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fulminant colitis should be admitted to a hospital and followed closely with vital signs and physical examination every four to six hours to evaluate abdominal and rebound tenderness and more frequently if there is clinical deterioration. Stool output should be recorded to chart the number and character of bowel movements, including the presence or absence of blood and liquid versus solid stool. A complete blood count, serum electrolytes, serum albumin, liver function tests, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) should be checked every 12 to 24 hours and more frequently if there is clinical deterioration. Patients should be managed by gastroenterologists and colorectal surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/1,25\">",
"     1,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with fulminant ulcerative colitis should be kept NPO. Nutritional support should be considered if the patient is malnourished. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H642204851#H642204851\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Nutritional assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link&amp;anchor=H3593887#H3593887\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\", section on 'Dietary interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous fluid and electrolyte replacement are necessary to correct and prevent dehydration or electrolyte imbalance. Blood transfusions may be needed to maintain a hemoglobin &ge;10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Patients with intestinal dilation (transverse colon diameter &ge;5.5 cm) should receive decompression with a nasoenteric tube. Intermittent rolling maneuvers every two hours or the knee-elbow position should be recommended to help redistribute gas in the colon and thereby promote decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Plain abdominal radiography should be repeated if there is clinical deterioration to determine if there is colonic dilation (diameter &ge;5.5 cm) or toxic megacolon (diameter &ge;6 cm or cecum &gt;9 cm and systemic toxicity).",
"   </p>",
"   <p>",
"    Patients with fulminant colitis should be treated with intravenous glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     Prednisolone",
"    </a>",
"    (30 mg IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (16 to 20 mg IV every eight hours) are preferred because they produce less sodium-retention and potassium-wasting.",
"   </p>",
"   <p>",
"    All patients with fulminant disease should be treated with broad-spectrum antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    400 mg every 12 hours and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg every eight hours).",
"   </p>",
"   <p>",
"    All patients should receive pharmacological venous thromboembolism prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) to reduce the risk of thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Pharmacologic agents for VTE prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Subsequent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fulminant ulcerative colitis who fail to improve by the third day of intensive treatment should be managed as patients with steroid-refractory ulcerative colitis with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , or undergo colectomy. However, the threshold to undergo colectomy in patients who fail to respond to cyclosporine or infliximab is lower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465825012\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has a role in induction of remission in patients with severe or fulminant colitis, but is not effective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    safe for long-term use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Cyclosporine is used as a short-term \"bridge\" to therapy with the slower onset, longer acting medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) or 6-mercaptopurine (6-MP). The role of cyclosporine in steroid-refractory ulcerative colitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465825019\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    can induce remission rapidly and can be used for the maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3319/abstract/30\">",
"     30",
"    </a>",
"    ]. However, it is unclear if anti-tumor necrosis factor (anti-TNF) therapy can prevent or reduce rates of colectomy in the long term. We therefore suggest infliximab in patients with an allergy to",
"    <span class=\"nowrap\">",
"     AZA/6-MP",
"    </span>",
"    or who have failed to",
"    <span class=\"nowrap\">",
"     AZA/6-MP.",
"    </span>",
"    The role of infliximab in steroid-refractory ulcerative colitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"     \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Steroid-refractory ulcerative colitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465825026\">",
"    <span class=\"h3\">",
"     Colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fulminant colitis who fail treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (either due to a failure to respond or due to relapse) within four to seven days and those with toxic megacolon (diameter &ge;6 cm or cecum &gt;9 cm and systemic toxicity) who do not respond to therapy within 72 hours, require colectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H527391152#H527391152\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link&amp;anchor=H12#H12\">",
"     \"Toxic megacolon\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"       \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient presents with symptoms suggestive of severe or fulminant ulcerative colitis, it is important to exclude alternative",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      comorbid conditions as a cause for their symptoms. Evaluation should consist of laboratory studies, stool studies, flexible sigmoidoscopy, and plain abdominal radiography. (See",
"      <a class=\"local\" href=\"#H1133540027\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365826359\">",
"    <span class=\"h2\">",
"     Severe ulcerative colitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a severe ulcerative colitis have frequent loose bloody stools (&ge;6 per day) with severe cramps and evidence of systemic toxicity as demonstrated by a fever (temperature &ge;37.5&deg;C), tachycardia (heart rate [HR] &ge;90",
"      <span class=\"nowrap\">",
"       beats/minute),",
"      </span>",
"      anemia (hemoglobin &lt;10.5",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      or an elevated erythrocyte sedimentation rate (ESR) (&ge;30",
"      <span class=\"nowrap\">",
"       mm/hour).",
"      </span>",
"      Patients may have rapid weight loss. (See",
"      <a class=\"local\" href=\"#H1133536041\">",
"       'Treatment of severe ulcerative colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe ulcerative colitis, we recommend treatment with oral glucocorticoids and high dose oral 5-ASA, and topical 5-ASA or steroids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Antibiotic therapy is used only in patients with signs of systemic toxicity. (See",
"      <a class=\"local\" href=\"#H1133540232\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients who continue to have severe symptoms despite optimal doses of oral glucocorticoids, high dose oral 5-ASA and topical 5-ASA, or steroids should be hospitalized for further management, including intravenous fluids and electrolytes. We recommend treatment with intravenous glucocorticoids in these patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1133540232\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who respond, intravenous glucocorticoids should be converted to equivalent oral dose and then gradually discontinued. We recommend oral 5-ASA medications for maintenance therapy in patients with severe ulcerative colitis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H324559250\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe ulcerative colitis with &gt;2 relapses requiring glucocorticoids in 12 months despite optimal doses of oral 5-ASA medication, patients who cannot tolerate oral 5-ASA medication, and patients with steroid-dependant ulcerative colitis should be treated with",
"      <span class=\"nowrap\">",
"       6-mercaptopurine/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"        azathioprine",
"       </a>",
"      </span>",
"      (AZA) or an anti-tumor necrosis factor (anti-TNF) agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An approach to patients with steroid-dependant ulcerative colitis and the administration, safety, and monitoring of AZA and 6-MP are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H526355188#H526355188\">",
"       \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Steroid-dependent ulcerative colitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H11#H11\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12573826\">",
"    <span class=\"h2\">",
"     Fulminant colitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fulminant colitis refers to a subgroup of patients with severe ulcerative colitis who have more than 10 stools per day, continuous bleeding, abdominal pain, and distension, and acute, severe toxic symptoms including fever and anorexia. (See",
"      <a class=\"local\" href=\"#H1133536048\">",
"       'Treatment of fulminant ulcerative colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with fulminant ulcerative colitis should be admitted to a hospital, closely monitored, and kept NPO. We recommend treatment with intravenous fluids, broad spectrum antibiotics, and intravenous glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1133536814\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not respond to intravenous glucocorticoids after three days, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H465825012\">",
"       'Cyclosporine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H465825019\">",
"       'Infliximab'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H14#H14\">",
"       \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Steroid-refractory ulcerative colitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with fulminant colitis who fail treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (either due to a failure to respond or due to relapse) within four to seven days, and those with toxic megacolon who do not respond to therapy within 72 hours, require colectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H527391152#H527391152\">",
"       \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Surgery'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"       \"Surgical management of ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/1\">",
"      Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/2\">",
"      Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982; 306:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/3\">",
"      Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/4\">",
"      Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/5\">",
"      Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/6\">",
"      McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/7\">",
"      Gonz&aacute;lez-Huix F, Fern&aacute;ndez-Ba&ntilde;ares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/8\">",
"      Roediger WE. The starved colon--diminished mucosal nutrition, diminished absorption, and colitis. Dis Colon Rectum 1990; 33:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/9\">",
"      Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/10\">",
"      Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007; 102:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/11\">",
"      Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5:V1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/12\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/13\">",
"      Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/14\">",
"      Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/15\">",
"      Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/16\">",
"      Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/17\">",
"      Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/18\">",
"      Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/19\">",
"      Cohen RD, Hanauer SB. Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr Opin Gastroenterol 1995; 11:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/20\">",
"      George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/21\">",
"      Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/22\">",
"      Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/23\">",
"      Ord&aacute;s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/24\">",
"      Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9:CD000478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/25\">",
"      Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut 2012; 61:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/26\">",
"      Present DH, Wolfson D, Gelernt IM, et al. Medical decompression of toxic megacolon by \"rolling\". A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol 1988; 10:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/27\">",
"      Panos MZ, Wood MJ, Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 1993; 34:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/28\">",
"      Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/29\">",
"      Cohen RD. How should we treat severe acute steroid-refractory ulcerative colitis? Inflamm Bowel Dis 2009; 15:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3319/abstract/30\">",
"      J&auml;rnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4068 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.150-A482A0459F-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3319=[""].join("\n");
var outline_f3_15_3319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1133540027\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1133536041\">",
"      TREATMENT OF SEVERE ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1133540232\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1239353307\">",
"      Subsequent therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H324559250\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1133536048\">",
"      TREATMENT OF FULMINANT ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1133536814\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Subsequent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H465825012\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H465825019\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H465825026\">",
"      - Colectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365826359\">",
"      Severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12573826\">",
"      Fulminant colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=related_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=related_link\">",
"      Nutrition and dietary interventions in adults with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=related_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3320="Tinea versicolor";
var content_f3_15_3320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tinea versicolor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3320/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/15/3320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea versicolor (ie, pityriasis versicolor) is a common superficial fungal infection. Patients with this disorder often present with hypopigmented, hyperpigmented, or erythematous macules on the trunk and proximal upper extremities. Unlike other disorders utilizing the term tinea (eg, tinea pedis, tinea capitis), tinea versicolor is not a dermatophyte infection. The causative organisms are saprophytic, lipid-dependent yeasts in the genus Malassezia (formerly known as Pityrosporum) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tinea versicolor responds well to medical therapy, but recurrence is common and long-term prophylactic therapy may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tinea versicolor occurs worldwide, but the highest incidence is found in tropical climates. Prevalence of up to 50 percent has been reported in some tropical countries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/2\">",
"     2",
"    </a>",
"    ]. In Scandinavia, the prevalence has been estimated to be approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tinea versicolor most commonly affects adolescents and young adults, but can also occur in children and has been reported in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The disorder is not contagious, although successful inoculation has occurred under experimental conditions utilizing topical oils and occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malassezia is a lipid-dependent, dimorphic fungus that is a component of normal skin flora. Transformation of Malassezia from yeast cells to a pathogenic mycelial form is associated with the development of clinical disease. External factors suspected of contributing to this conversion include exposure to hot and humid weather, hyperhidrosis, and the use of topical skin oils [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/9\">",
"     9",
"    </a>",
"    ]. Tinea versicolor is not related to poor hygiene.",
"   </p>",
"   <p>",
"    Host characteristics that contribute to the development of tinea versicolor are poorly understood. A genetic predisposition may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/10\">",
"     10",
"    </a>",
"    ]. In a questionnaire-based study, 21 percent of patients reported a positive family history of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/11\">",
"     11",
"    </a>",
"    ]. Tinea versicolor also occurs more commonly in patients who are immunosuppressed, suggesting that an altered host immune response may play a role in the pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/12\">",
"     12",
"    </a>",
"    ]. Oral contraceptive therapy and malnutrition may be additional predisposing factors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. globosa appears to be the predominant causal species in tinea versicolor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. M. sympodialis, M. furfur, and other Malassezia species have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6021?source=see_link\">",
"     \"Malassezia infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"versicolor\" refers to the variable changes in cutaneous pigmentation that may occur in this disorder. Lesions can be hypopigmented, hyperpigmented, or mildly erythematous (",
"    <a class=\"graphic graphic_picture graphicRef59533 graphicRef72396 graphicRef52438 graphicRef73839 \" href=\"UTD.htm?32/41/33434\">",
"     picture 1A-D",
"    </a>",
"    ). In light-skinned individuals, hyperpigmented lesions are often light brown (",
"    <a class=\"graphic graphic_picture graphicRef78860 \" href=\"UTD.htm?13/17/13588\">",
"     picture 2",
"    </a>",
"    ). Hyperpigmented tinea versicolor may present as dark brown to gray-black macules and patches in those with dark skin (",
"    <a class=\"graphic graphic_picture graphicRef52438 \" href=\"UTD.htm?15/22/15712\">",
"     picture 1C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lesion color can vary between individuals with similar skin color, and occasionally, between lesions on one person. Although the reasons for pigmentary variation are unconfirmed, a few theories have been proposed. Patients with hypopigmented tinea versicolor often notice that the disorder is most prominent during the summer, when the affected areas fail to tan after sun exposure. Inhibitory or damaging effects on melanocytes by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    (a dicarboxylic acid produced by Malassezia) may play a role in the development of these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Hyperpigmented and erythematous lesions may be a consequence of an inflammatory reaction to the yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fine scale is often present on affected skin, which becomes more apparent when the lesion is scraped for microscopy. Individual lesions are typically small, but frequently coalesce into larger patches. In adolescents and adults, tinea versicolor is most commonly found on the upper trunk and proximal upper extremities, and less often on the face and intertriginous areas. In contrast, when tinea versicolor occurs in children, it is likely to involve the face [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of tinea versicolor on the body may reflect the nutritional requirements of the yeast. Malassezia is lipid-dependent, and the greater sebum production by cutaneous sebaceous glands on the upper body may contribute to the predominance of tinea versicolor in this location. This theory may also account for the less frequent occurrence of this disorder in children and the elderly, in whom sebum production is less [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While most patients are asymptomatic, some complain of mild pruritus, and many are concerned about cosmesis. Although spontaneous remission has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/20\">",
"     20",
"    </a>",
"    ], the disorder can be persistent if untreated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variable clinical features of tinea versicolor and the existence of other skin disorders with similar findings make it preferable to confirm the diagnosis with a potassium hydroxide (KOH) preparation. Both hyphae and yeast cells are evident in a pattern that is often described as \"spaghetti and meatballs\" (",
"    <a class=\"graphic graphic_picture graphicRef58965 \" href=\"UTD.htm?29/33/30228\">",
"     picture 3",
"    </a>",
"    ). Additionally, in approximately one-third of cases, examination with a Wood's lamp will reveal yellow to yellow-green fluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of tinea versicolor consists of several common and uncommon skin disorders. The KOH preparation is a simple and reliable way to confirm the diagnosis. Examples of skin disorders that may resemble tinea versicolor include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Seborrheic dermatitis &mdash;",
"      </strong>",
"      Seborrheic dermatitis on the trunk is usually more erythematous than tinea versicolor, and typically has thicker scale. Patients often exhibit other areas of involvement such as the scalp, eyebrows, and nasolabial folds (",
"      <a class=\"graphic graphic_picture graphicRef56410 \" href=\"UTD.htm?33/58/34721\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of dermatitis\", section on 'Seborrheic dermatitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=see_link&amp;anchor=H34051773#H34051773\">",
"       \"Seborrheic dermatitis in adolescents and adults\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis rosea &mdash;",
"      </strong>",
"      Patients with classic pityriasis rosea present with inflammatory macules and small patches in a \"Christmas tree-like\" distribution on the trunk. A larger herald patch that precedes the widespread eruption is often noted. Lesions are erythematous, and exhibit a collarette of scale (",
"      <a class=\"graphic graphic_picture graphicRef87126 \" href=\"UTD.htm?34/61/35793\">",
"       picture 5",
"      </a>",
"      ). In dark-skinned individuals, hyperpigmentation can be prominent (",
"      <a class=\"graphic graphic_picture graphicRef53701 \" href=\"UTD.htm?13/6/13414\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/18999?source=see_link\">",
"       \"Pityriasis rosea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vitiligo &mdash;",
"      </strong>",
"      Vitiligo is characterized by completely depigmented macules and patches (",
"      <a class=\"graphic graphic_picture graphicRef79198 \" href=\"UTD.htm?12/53/13139\">",
"       picture 7",
"      </a>",
"      ). In contrast, tinea versicolor exhibits hypopigmented skin lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=see_link\">",
"       \"Vitiligo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythrasma &mdash;",
"      </strong>",
"      Erythrasma may present with erythematous or hyperpigmented patches in the axillae or groin, and is included in the differential diagnosis of intertriginous tinea versicolor (",
"      <a class=\"graphic graphic_picture graphicRef59529 graphicRef51713 \" href=\"UTD.htm?2/28/2504\">",
"       picture 8A-B",
"      </a>",
"      ). Lesions of erythrasma exhibit coral red fluorescence upon illumination with a Wood's lamp (",
"      <a class=\"graphic graphic_picture graphicRef62143 \" href=\"UTD.htm?37/27/38321\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=see_link\">",
"       \"Erythrasma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis alba &mdash;",
"      </strong>",
"      Pityriasis alba is a mild form of eczematous dermatitis that presents with hypopigmented macules and small patches on the face, and less frequently on the upper extremities (",
"      <a class=\"graphic graphic_picture graphicRef60866 graphicRef73576 \" href=\"UTD.htm?14/55/15219\">",
"       picture 10A-B",
"      </a>",
"      ). Fine scale may be visible. The disorder is most common in children with an atopic history. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to the patient with macular skin lesions\", section on 'Pityriasis alba'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary syphilis &mdash;",
"      </strong>",
"      Patients with secondary syphilis may present with erythematous to brown macules, papules, or small plaques in a generalized distribution (",
"      <a class=\"graphic graphic_picture graphicRef68877 \" href=\"UTD.htm?9/3/9279\">",
"       picture 11",
"      </a>",
"      ). Lesions are often present on the palms and soles (",
"      <a class=\"graphic graphic_picture graphicRef65500 \" href=\"UTD.htm?6/6/6242\">",
"       picture 12",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Confluent and reticulated papillomatosis of Gougerot and Carteaud &mdash;",
"      </strong>",
"      This uncommon cutaneous disorder usually occurs in young adults. Hyperpigmented, scaly patches with a reticulated appearance are present (",
"      <a class=\"graphic graphic_picture graphicRef67566 graphicRef76296 graphicRef54172 graphicRef66671 \" href=\"UTD.htm?40/51/41786\">",
"       picture 13A-D",
"      </a>",
"      ). The neck, chest (particularly intermammary area), and upper back may be affected.",
"     </li>",
"     <li>",
"      <strong>",
"       Mycosis fungoides &mdash;",
"      </strong>",
"      Mycosis fungoides may present as hypopigmented patches on the skin, with a predilection for the trunk and extremities (",
"      <a class=\"graphic graphic_picture graphicRef71926 \" href=\"UTD.htm?33/38/34402\">",
"       picture 14",
"      </a>",
"      ). This variant of the disorder occurs most commonly in individuals with dark skin. Fine scale, erythema, or infiltrated plaques may also be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy is the treatment of choice for patients with limited disease. Systemic therapy is typically reserved for patients with widespread or recurrent tinea versicolor, or who have failed topical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be advised that changes in cutaneous pigment often remain after treatment. Restoration of even pigmentation may take months after the completion of successful therapy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of topical medications are effective for the management of tinea versicolor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment regimens in the literature vary widely, with durations of treatment ranging from days to weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Topical antifungals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple small randomized and open label studies have supported the efficacy of topical azole antifungals (",
"    <a class=\"graphic graphic_table graphicRef76148 \" href=\"UTD.htm?19/3/19517\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"     1",
"    </a>",
"    ]. In one randomized trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream once daily for 11 to 22 days (mean 14 days) was superior to placebo (84 versus 22 percent achieved mycological cure) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/22\">",
"     22",
"    </a>",
"    ]. Ketoconazole is also available as a gel or foam.",
"   </p>",
"   <p>",
"    The shampoo formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    has also been studied for the treatment of tinea versicolor, and appears to be effective with a relatively short duration of therapy. The shampoo is applied to affected areas, and is washed off after five minutes. In a randomized trial, a single application of ketoconazole 2% shampoo was compared with repeated treatments on three consecutive days. Both regimens resulted in mycologic cure in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small randomized trials and uncontrolled studies have shown that other azole antifungals are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/2\">",
"     2",
"    </a>",
"    ]. A two week course of these agents is likely to be sufficient in most cases.",
"   </p>",
"   <p>",
"    Treatment with other topical antifungals can be successful. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    applied twice daily for one week has been proven effective in small randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    olamine was also effective in two small randomized trials when applied twice daily for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Selenium sulfide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"     Selenium sulfide",
"    </a>",
"    , a topical medication that exerts antifungal activity primarily through the promotion of shedding of the infected stratum corneum, is frequently prescribed for this condition. In a randomized trial, application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    sulfide 2.5% lotion for 10 minutes for seven days was superior to placebo in achieving mycologic cure (81 versus 15 percent cured, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/27\">",
"     27",
"    </a>",
"    ]. The shampoo formulation of selenium sulfide 2.5% is often prescribed in clinical practice. A non-prescription selenium sulfide 1% shampoo is also available, but the efficacy of this product for the treatment of tinea versicolor has not been studied. Selenium sulfide 2.25% foam is a newer product that is applied twice daily without rinsing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these products have been less extensively studied, zinc pyrithione, propylene glycol, sulfur with salicylic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    , and Whitfield's ointment have also been used for the treatment of tinea versicolor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral azole antifungals such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    are effective for the treatment of tinea versicolor. In contrast to topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    , oral terbinafine is not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    cannot be used for this condition.",
"   </p>",
"   <p>",
"    Oral azole antifungals are typically reserved for patients with recalcitrant tinea versicolor or widespread disease that makes the application of topical drugs difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. Abnormalities in liver function tests can occur with all azole antifungals. Drug interactions may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of azoles\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two small, randomized trials, 200 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    for five days was a successful treatment for more than 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A single 400 mg dose was also effective in a small uncontrolled study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/31\">",
"     31",
"    </a>",
"    ], but may be less effective than treatment with multiple doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/32\">",
"     32",
"    </a>",
"    ]. Life-threatening hepatotoxicity has been reported with ketoconazole therapy, but appears to be rare with the short duration of therapy used for tinea versicolor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of azoles\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials have reported mycologic cure rates between 70 and 100 percent with 200 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    daily for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"     1",
"    </a>",
"    ]. Dose comparison studies have shown similar success with treatment durations of five days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"     1",
"    </a>",
"    ]. A single, 400 mg dose of itraconazole is another therapeutic option. In a randomized, open label trial the single 400 mg dose was as effective as 200 mg daily for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small, uncontrolled study, 300 mg once weekly for two weeks led to mycologic and clinical cure in 75 percent of patients with tinea versicolor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/35\">",
"     35",
"    </a>",
"    ]. A dose-finding randomized trial also supports the efficacy of this regimen; 300 mg once weekly for up to two weeks resulted in mycologic cure in 87 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    also appears to be effective. In an uncontrolled study of 24 individuals with extensive or recurrent tinea versicolor treated with a single 400 mg dose of fluconazole, resolution of clinical disease occurred in 74 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pramiconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pramiconazole, a newer triazole antifungal, has been studied for the treatment of tinea versicolor. In a randomized trial, pramiconazole was superior to placebo at doses of 200 mg for two days, 200 mg for three days, and single doses of 200 mg or 400 mg (mycologic cure rates of 92, 96, 68, and 78 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/38\">",
"     38",
"    </a>",
"    ]. The drug is not yet available for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Comparison studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide variations in treatment regimens and conflicting results of published studies compromise assessments of the relative efficacy of treatments for tinea versicolor. In addition, a systematic review and meta-analysis of controlled trials found that most trials that compared treatment regimens or therapeutic agents were underpowered to detect meaningful differences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/32\">",
"     32",
"    </a>",
"    ]. The results suggested that longer courses of treatment, higher concentrations of topical active ingredients, and higher doses of oral antifungals may improve cure rates; however additional studies are necessary to confirm these findings.",
"   </p>",
"   <p>",
"    Topical therapies have been directly compared to systemic antifungal regimens in two open-label randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial that compared a variety of treatment regimens, 194 patients were treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (two or three 300 mg doses separated by one week) and 36 patients were treated with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      (1% cream applied twice daily for 21 days). The two agents were similarly effective [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of 40 patients with tinea versicolor found similar rates of clinical resolution (absence of scale and negative Wood&rsquo;s lamp examination) among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg once daily for five days) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"       selenium sulfide",
"      </a>",
"      (once daily application for seven days) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/40\">",
"       40",
"      </a>",
"      ]. However, three weeks after the completion of therapy, small numbers of yeast and hyphae were detected on potassium hydroxide (KOH) preparations in approximately 40 percent of the patients with clinical resolution who had been treated with itraconazole, compared with none of the patients who achieved clinical cure with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      sulfide. Follow-up for clinical recurrence was not performed, and the implications of the detection of a few fungal hyphae in the absence of clinical signs of active disease were unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the lack of high quality evidence on the relative efficacy of treatments for tinea versicolor, factors such as safety, patient preference, and drug availability and cost may influence the choice of therapy. In general, we treat most patients with tinea versicolor with a topical regimen, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampoo, and utilize systemic therapy for those with widespread, recurrent, or refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopigmentation and hyperpigmentation can persist for months following successful treatment of tinea versicolor, and may cause patients to assume incorrectly that treatment has failed. The presence of scale plus a positive KOH preparation is usually considered indicative of active infection.",
"   </p>",
"   <p>",
"    Resistance to therapy, frequent recurrence, or widespread disease should prompt consideration of an immunodeficient state (",
"    <a class=\"graphic graphic_table graphicRef71244 \" href=\"UTD.htm?37/20/38220\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience frequent recurrences of tinea versicolor (particularly immunosuppressed individuals) can prevent recurrences with use of topical or oral preventive therapy, particularly during warm weather. In our clinical experience, prophylaxis with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"     selenium sulfide",
"    </a>",
"    2.5% or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampoo applied to the entire body for ten minutes once per month is an effective therapy.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    are also used for prophylaxis. In a six-month randomized trial, a greater percentage of subjects were free of recurrent disease after prophylactic treatment with itraconazole (200 mg twice daily for one day per month) than with placebo (88 percent versus 57 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/41\">",
"     41",
"    </a>",
"    ]. Ketoconazole 400 mg one day per month was also reported to be effective for prophylaxis in a small, uncontrolled study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3320/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/47/24305?source=see_link\">",
"       \"Patient information: Tinea versicolor (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tinea versicolor is a common fungal skin infection. The disorder occurs worldwide, but is most prevalent in tropical climates. Adolescents and young adults are affected most frequently. Tinea versicolor is not contagious. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malassezia yeasts are a component of normal skin flora. The reasons for the development of tinea versicolor are likely to be multifactorial, involving both exogenous and endogenous factors. Immunosuppressed patients may be at increased risk for the disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with tinea versicolor can exhibit hypopigmented, hyperpigmented, or erythematous macules and patches. The most common areas of involvement include the upper trunk and proximal upper extremities; facial and intertriginous areas are less frequently affected. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potassium hydroxide preparation is a quick and effective way to diagnose tinea versicolor. A Wood's lamp examination will reveal yellow to yellow-green fluorescence in a minority of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical therapy is a safe and effective treatment for most patients with tinea versicolor. Based upon ease of use, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% shampoo (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients should be advised that pigmentary changes may take months to resolve. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Topical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with extensive disease, we suggest treatment with an oral azole antifungal rather than topical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically use a single 400 mg dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with tinea versicolor who fail topical therapy can be treated with a systemic agent. Treatment regimens are the same as for patients with extensive disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent disease is common. For patients who desire treatment and experience multiple recurrences per year, we suggest prophylactic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically use once monthly application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"       selenium sulfide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      shampoo. If this regimen is not effective, we prescribe 400 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      once monthly during the warm months of the year, when recurrence is most likely. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/1\">",
"      Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin 2003; 21:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/2\">",
"      Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/3\">",
"      Bouassida S, Boudaya S, Ghorbel R, et al. [Pityriasis versicolor in children: a retrospective study of 164 cases]. Ann Dermatol Venereol 1998; 125:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/4\">",
"      Nanda A, Kaur S, Bhakoo ON, et al. Pityriasis (tinea) versicolor in infancy. Pediatr Dermatol 1988; 5:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/5\">",
"      Jena DK, Sengupta S, Dwari BC, Ram MK. Pityriasis versicolor in the pediatric age group. Indian J Dermatol Venereol Leprol 2005; 71:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/6\">",
"      Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol 1981; 117:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/7\">",
"      Faergemann J, Fredriksson T. Experimental infections in rabbits and humans with Pityrosporum orbiculare and P. ovale. J Invest Dermatol 1981; 77:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/8\">",
"      BURKE RC. Tinea versicolor: susceptibility factors and experimental infection in human beings. J Invest Dermatol 1961; 36:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/9\">",
"      Faergemann J. Pityriasis versicolor. Semin Dermatol 1993; 12:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/10\">",
"      Hafez M, el-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica 1985; 171:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/11\">",
"      He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses 2008; 51:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/12\">",
"      G&uuml;le&ccedil; AT, Demirbilek M, Se&ccedil;kin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol 2003; 49:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/13\">",
"      Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol 1991; 25:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/14\">",
"      Morishita N, Sei Y. Microreview of Pityriasis versicolor and Malassezia species. Mycopathologia 2006; 162:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/15\">",
"      Prohic A, Ozegovic L. Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor. Mycoses 2007; 50:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/16\">",
"      Karaka�� M, Tura&ccedil;-Bi&ccedil;er A, Ilkit M, et al. Epidemiology of pityriasis versicolor in Adana, Turkey. J Dermatol 2009; 36:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/17\">",
"      Schwartz RA. Superficial fungal infections. Lancet 2004; 364:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/18\">",
"      Galadari I, el Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol 1992; 31:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/19\">",
"      Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978; 71:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/20\">",
"      Robertson LI. Itraconazole in the treatment of widespread tinea versicolor. Clin Exp Dermatol 1987; 12:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/21\">",
"      Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/22\">",
"      Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/23\">",
"      Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 1998; 39:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/24\">",
"      Savin R, Eisen D, Fradin MS, Lebwohl M. Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol 1999; 38:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/25\">",
"      Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology 1997; 194 Suppl 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/26\">",
"      Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/27\">",
"      S&aacute;nchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/28\">",
"      Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol 1997; 137:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/29\">",
"      Hay RJ, Midgeley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/30\">",
"      Zaias N. Pityriasis versicolor with ketoconazole. J Am Acad Dermatol 1989; 20:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/31\">",
"      Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1984; 34:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/32\">",
"      Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010; 146:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/33\">",
"      Goodless DR, Ramos-Caro FA, Flowers FP. Ketoconazole in the treatment of pityriasis versicolor: international review of clinical trials. DICP 1991; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/34\">",
"      K&ouml;se O, B&uuml;lent Ta��tan H, Riza G&uuml;r A, Kurumlu Z. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002; 13:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/35\">",
"      Karaka�� M, Durdu M, Memi��o��lu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol 2005; 32:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/36\">",
"      Amer MA. Fluconazole in the treatment of tinea versicolor. Egyptian Fluconazole Study Group. Int J Dermatol 1997; 36:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/37\">",
"      Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol 1992; 72:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/38\">",
"      Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol 2009; 61:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/39\">",
"      Silva H, Gibbs D, Arguedas J. A comparison of fluconazole with ketoconazole, itraconazole, and clotrimazole in the treatment of patients with pityriasis versicolor. Current Therapeutic Research. 1998; 59:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/40\">",
"      del Palacio Hernanz A, Delgado Vicente S, Men&eacute;ndez Ramos F, Rodr&iacute;guez-Noriega Belaustegui A. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9 Suppl 1:S121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3320/abstract/41\">",
"      Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002; 138:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4039 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3320=[""].join("\n");
var outline_f3_15_3320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Topical antifungals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Selenium sulfide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pramiconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Comparison studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4039|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/16/10496\" title=\"picture 1A\">",
"      Tinea versicolor arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/23/19827\" title=\"picture 1B\">",
"      Tinea versicolor back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/22/15712\" title=\"picture 1C\">",
"      Tinea versicolor chest 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/9/20630\" title=\"picture 1D\">",
"      Tinea versicolor shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/17/13588\" title=\"picture 2\">",
"      Tinea versicolor chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30228\" title=\"picture 3\">",
"      Tinea versicolor KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/58/34721\" title=\"picture 4\">",
"      Seborrheic dermatitis face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/61/35793\" title=\"picture 5\">",
"      Pityriasis rosea with herald patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/6/13414\" title=\"picture 6\">",
"      Pityriasis rosea dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/53/13139\" title=\"picture 7\">",
"      Vitiligo generalized",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/13/29905\" title=\"picture 8A\">",
"      Erythrasma in axilla 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/36/43587\" title=\"picture 8B\">",
"      Intertriginous erythrasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/27/38321\" title=\"picture 9\">",
"      Erythrasma fluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/30/33262\" title=\"picture 10A\">",
"      Pityriasis alba 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/29/22992\" title=\"picture 10B\">",
"      Pityriasis alba 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/3/9279\" title=\"picture 11\">",
"      Rash in secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/6/6242\" title=\"picture 12\">",
"      Palmar rash secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/10/36003\" title=\"picture 13A\">",
"      Confluent and reticulated papillomatosis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/8/25729\" title=\"picture 13B\">",
"      Confluent and reticulated papillomatosis - chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/36/40518\" title=\"picture 13C\">",
"      Confluent and reticulated papillomatosis - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/40/647\" title=\"picture 13D\">",
"      Confluent and reticulated papillomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/38/34402\" title=\"picture 14\">",
"      Hypopigmented mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4039|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/3/19517\" title=\"table 1\">",
"      Topical antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/20/38220\" title=\"table 2\">",
"      Conditions assoc second imm def",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11959?source=related_link\">",
"      Erythrasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6021?source=related_link\">",
"      Malassezia infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/47/24305?source=related_link\">",
"      Patient information: Tinea versicolor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/18999?source=related_link\">",
"      Pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=related_link\">",
"      Vitiligo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3321="Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis";
var content_f3_15_3321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3321/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3321/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3321/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3321/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3321/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/15/3321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15769692\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener&rsquo;s will be phased out after several years as the new name becomes more widely known",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), have similar features on renal histology (eg, a focal necrotizing, pauci-immune, crescentic glomerulonephritis), and have similar outcomes. There are, however, several differences between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with life-threatening or organ-threatening disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in combination with glucocorticoids is the standard of care for initial immunosuppressive therapy, although two randomized trials with limited follow-up have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was as effective as cyclophosphamide in inducing remission of patients with newly diagnosed or relapsing GPA or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant GPA or MPA will be reviewed here. Initial and maintenance immunosuppressive therapy, the clinical manifestations and diagnosis of these diseases, the treatment of relapsing disease, and patient and renal outcomes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;True",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistance in granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and MPA is defined as the presence of active disease affecting a major organ despite optimal initial immunosuppressive therapy with cyclophosphamide and glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies from the University of North Carolina defined treatment resistance as one or both of the following despite immunosuppressive therapy for at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A progressive decline in renal function (ie, increase in serum creatinine) plus persistence of an active urine sediment (ie, dysmorphic hematuria with or without red cell casts)",
"     </li>",
"     <li>",
"      Persistence or new appearance of extrarenal manifestations of active vasculitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients are incorrectly considered to be",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant. An important cause is failure to distinguish correctly between active disease and signs of permanent damage induced by previous inflammatory injury. As an example, an elevated serum creatinine with or without proteinuria that can reach the nephrotic range can reflect chronic injury with scarring and is not considered a sign of active renal disease in the absence of dysmorphic (glomerular) hematuria (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"UTD.htm?40/13/41170\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H1824471562#H1824471562\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Red cell morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that can lead to an incorrect diagnosis of persistent active disease include the presence of other diseases, noncompliance, an inadequate induction regimen, and the development of medication toxicities (eg, infection) that may present with manifestations similar to active disease. Thus, clinical judgment is essential when deciding that a patient is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cannot take cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients have a contraindication to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy or refuse such therapy because of concerns about fertility, hair loss, the risk of malignancy, or other issues.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is the drug of choice for such patients since, in two randomized trials, rituximab was as effective as cyclophosphamide in inducing remission among patients with newly diagnosed or relapsing GPA or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A potential limitation is that the duration of follow-up was limited to six to twelve months compared with the extensive long-term experience with cyclophosphamide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H16198972#H16198972\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Unresponsive but not resistant",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least two disease manifestations that may be relatively unresponsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (and to other systemic therapies), but are NOT considered resistant disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orbital pseudotumor (retrobulbar inflammatory masses).",
"     </li>",
"     <li>",
"      Subglottic stenosis, which may reflect scar rather than ongoing inflammation, and may respond best to local therapies such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      injections and dilatation procedures (avoiding laser therapies). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H27#H27\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Management of upper airway involvement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of true",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistance appears to be lower in clinical trials than clinical practice. In three major randomized clinical trials in ANCA-associated vasculitis, approximately 90 percent of patients in each of the trials achieved disease remission within six months of treatment and 10 percent are resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. By comparison, higher rates of resistant disease have been observed in clinical practice. This was illustrated in a community-based cohort study of 350 patients who received a new diagnosis of ANCA-associated vasculitis between 1985 and 2003 and were followed by physicians in the Glomerular Disease Collaborative Network [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistance, as defined in the preceding section, occurred in 23 percent of patients; 82 percent of these patients were treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -based regimen and the remaining patients were treated with glucocorticoids alone or with other drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil.",
"     </li>",
"     <li>",
"      The likelihood of resistance was significantly lower with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared to glucocorticoids alone (adjusted odds ratio 0.43).",
"     </li>",
"     <li>",
"      Resistance was more likely in patients with severe kidney disease at presentation (odds ratio 1.28 per 1.13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [100",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      elevation in serum creatinine). However, although treatment resistant patients had a higher mean serum creatinine than responders (6.7 versus 4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [590 versus 353",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      therapy was effective in the majority of these patients. Remission was induced in 72, 68, and 57 percent of patients with an estimated glomerular filtration rate of &le;30, &le;20, and &le;10",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Other significant risk factors included female sex and black ethnicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors included MPO-ANCA compared to PR3-ANCA, advanced age, and renal biopsy findings of chronic disease (eg, glomerular and vascular sclerosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA)have a much worse prognosis than patients who respond. The rate of progression to end-stage renal disease according to the response to cyclophosphamide induction therapy was evaluated in the above series of 350 patients from the Glomerular Disease Collaborative Network [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/6\">",
"     6",
"    </a>",
"    ]. The renal prognosis was poor as 60 of 76 such patients (79 percent) developed end-stage renal disease at a median of two months after the initiation of therapy. The rate of end-stage renal disease was much lower in patients who attained remission with initial immunosuppressive therapy (19 percent at 9 years in patients who did not relapse and 28 percent at 5.5 years in those who relapsed).",
"   </p>",
"   <p>",
"    Patient and renal outcomes in patients with GPA or MPA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF CYCLOPHOSPHAMIDE-RESISTANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the management of the patient suspected of being",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant is to ensure that the clinical abnormalities are not due to drug toxicity, noncompliance, an inadequate regimen, progression of chronic inactive disease, infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathogenic processes other than ongoing inflammation.",
"   </p>",
"   <p>",
"    The optimal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimens and the role of plasma exchange in selected patients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Choice of cyclophosphamide regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Role of plasma exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of drugs have been examined in small numbers of patients with resistant disease. In many cases, an accurate interpretation of the results is difficult due to the presence of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manifestations of non-major organ involvement, such as constitutional features, upper airways disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arthralgias.",
"     </li>",
"     <li>",
"      Features suspicious for chronic sequelae rather than active disease.",
"     </li>",
"     <li>",
"      Subglottic stenosis which, as noted above, is often unresponsive to immunosuppressive therapy and may respond best to local therapies such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      injections and dilatation procedures (avoiding laser therapies). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Unresponsive but not resistant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Possibly effective therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No therapy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant disease has been proven to be effective in randomized controlled trials. Observational studies have suggested efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and rituximab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13942280\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials cited above found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in inducing remission of patients with newly diagnosed or relapsing granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA)at a follow-up of six to twelve months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, these trials did not include patients with resistant disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Cannot take cyclophosphamide'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H16198972#H16198972\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    plus glucocorticoids have been beneficial in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistance in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/11-19\">",
"     11-19",
"    </a>",
"    ]. The largest reported experience in resistant disease comes from a retrospective multicenter survey of 65 patients with cyclophosphamide-resistant ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/11\">",
"     11",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rates of complete and partial remission in 75 and 23 percent, respectively. The median time to remission was two months (range one to five months).",
"     </li>",
"     <li>",
"      Among the 49 patients who attained complete remission, 28 (57 percent) relapsed at a median of 12 months. Relapse was preceded by recovery of B cell counts in about one-half of cases. The likelihood of relapse appeared to be unrelated to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      regimen (either four weekly infusions of 375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      or two 1 g infusions given two weeks apart).",
"     </li>",
"     <li>",
"      A second course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      was given to 33 patients because of relapse or preemptive therapy to avoid relapse and to five patients because of persistent disease. Complete remission was induced or maintained in 32 of these patients (84 percent).",
"     </li>",
"     <li>",
"      Monitoring ANCA titers and B cell counts were not sufficiently sensitive to guide the timing of retreatment. Although ANCA titers fell after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy, relapse was not associated with either ANCA positivity or a rise in ANCA titers.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      was well tolerated. Two patients developed neutropenia at three and five months after the second course, and no other adverse event was directly attributable to rituximab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic and vasculitis-related symptoms may completely resolve within days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. In contrast, manifestations due to granuloma formation improve more slowly (over several weeks to months) or do not respond [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. One report, for example, evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in eight patients (five with retrobulbar granuloma, one with",
"    <span class=\"nowrap\">",
"     pulmonary/sinus",
"    </span>",
"    granuloma, and two with subglottic stenosis) who had not responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, or to anti-tumor necrosis factor-alpha therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/17\">",
"     17",
"    </a>",
"    ]. Improvement in disease manifestations was noted in the patient with",
"    <span class=\"nowrap\">",
"     pulmonary/sinus",
"    </span>",
"    granuloma and one of the patients with subglottic stenosis, but in none of the patients with retrobulbar disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Management of upper airway involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benefit has also been noted in patients with ophthalmic manifestations (eg, scleritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    granulomas causing optic nerve compromise) that were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in patients with GPA or MPA is needed in order to better understand its role in the management of these disorders, and whether development of antibodies limits its long-term usefulness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) has shown possible efficacy for maintenance immunosuppression and the treatment of relapses in patients with GPA or MPA. These data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link&amp;anchor=H6#H6\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of small observational studies have evaluated MMF in patients who were resistant to or could not tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to patients who are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , a pilot study of non-life-threatening disease included four patients who failed to improve after at least six months of cyclophosphamide-based induction therapy and two patients who had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    because cyclophosphamide could not be given [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/20\">",
"     20",
"    </a>",
"    ]. After cyclophosphamide was discontinued, the glucocorticoid dose was maintained and the patients were started on MMF (500 mg twice daily, which was increased by 250 mg twice daily every two weeks to a maximum dose of 1500 mg twice daily in patients who showed no evidence of response to 1000 mg twice daily). Six other patients had frequently relapsing disease and were included in the analysis. Among the 10 patients who completed the study (target dose given for 24 weeks), improvement in disease activity occurred in all patients and six had at least a transient complete remission.",
"   </p>",
"   <p>",
"    MMF was also evaluated for remission induction in 32 consecutive patients who had ANCA-associated vasculitis for a median of six years, had a median of four relapses prior to the current relapse, and could not be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/22\">",
"     22",
"    </a>",
"    ]. Cyclophosphamide was considered contraindicated for a variety of reasons including previous hemorrhagic cystitis on cyclophosphamide, treated bladder cancer, bone marrow depression, patient refusal, and, in six patients, an incomplete response to or relapse during cyclophosphamide therapy.",
"   </p>",
"   <p>",
"    Complete or partial remissions were induced in 78 and 19 percent, respectively. Relapse during follow-up occurred in 19 of 25 patients (76 percent) who attained complete remission and in all six who attained partial remission. The patients who had been treated unsuccessfully with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    had a worse response than those had previously responded (complete remission 50 versus 84 percent, relapse 100 versus 50 percent).",
"   </p>",
"   <p>",
"    The possible efficacy of MMF for maintenance therapy after remission of active disease has been induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link&amp;anchor=H6#H6\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Therapies of unproven efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Anti-TNF-alpha therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insights into the role of Th1 cytokines in the pathogenesis of GPA have led to on-going trials involving therapy with antagonists to tumor necrosis factor-alpha (TNFa) and inhibitors of monocyte function, such as interleukin-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/23\">",
"     23",
"    </a>",
"    ]. The rationale for such therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\", section on 'Role of T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited on the possible efficacy of these agents in GPA or MPA and there is possible harm. In a major randomized trial of patients with GPA who were not resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (Wegener's Granulomatosis",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    Trial), etanercept was ineffective in maintaining remission and was associated with a higher rate of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an open label study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was added to standard immunosuppressive therapy in 16 patients with acute ANCA-associated vasculitis at first presentation or relapse and in 16 with persistent disease despite multiple immunosuppressive regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/24\">",
"     24",
"    </a>",
"    ]. Fourteen patients in each group (88 percent) achieved remission within a mean of 6.4 weeks. Serious infections and death were reported in seven and two patients, respectively, while five patients (three with persistent disease) had a relapse at a mean of 27 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role, if any, of TNFa inhibitors for the treatment of GPA or MPA remains unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anti-T cell antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that active systemic vasculitis is mediated in part by T cell-induced injury has led to the evaluation of anti-T cell antibodies in patients with GPA who are resistant to or cannot tolerate cytotoxic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the administration of a combination of two humanized monoclonal antibodies (one directed against an antigen on all mononuclear cells and one directed against CD4) led to long-lasting remission in four patients with different forms of refractory vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/25\">",
"       25",
"      </a>",
"      ]. This was also accompanied by toxicity that included infusion reactions, infection, autoimmune events, and prolonged lymphocyte depletion.",
"     </li>",
"     <li>",
"      Among 15 patients with refractory disease (seven unresponsive to and eight intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ), anti-thymocyte globulin (ATG) resulted in a partial or complete remission in 9 and 4 patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/27\">",
"       27",
"      </a>",
"      ]. However, two patients died one and three days after the first administration of ATG (due to pulmonary hemorrhage and infection).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of these experimental therapies remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin has been studied in only a limited fashion in ANCA-associated vasculitis, and none of the available studies provide clear answers regarding potential efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. The best data come from a randomized, placebo-controlled trial of 34 patients with ANCA-associated systemic vasculitis and persistent disease activity despite previous immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/31\">",
"     31",
"    </a>",
"    ]. Improvement occurred in 6 of 13 who had lung involvement but no information was provided regarding the presence or response of renal manifestations of the disease. The uncertain efficacy of intravenous immune globulin has led many investigators to be hesitant about its use in ANCA-associated systemic vasculitis. A review of the mechanisms of action and potential side effects associated with this modality can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Intravenous azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are anecdotal reports of using high dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    to treat a variety of immune-mediated diseases. In one report, four patients with GPA who had not responded to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) were treated with monthly infusions of azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/32\">",
"     32",
"    </a>",
"    ]. Two had remission of disease, one of whom developed renal involvement during relapse, which responded to retreatment.",
"   </p>",
"   <p>",
"    In the absence of further data, high dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    should NOT be used for the treatment of ANCA-associated systemic vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     15-Deoxyspergualin",
"    </span>",
"    &nbsp;&mdash;&nbsp;15-deoxyspergualin (gusperimus), which has an antiproliferative effect on antigen-stimulated B cells, has been evaluated in a small number of patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant disease or contraindications to the use of cyclophosphamide:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 20 such patients, the administration of 15-deoxyspergualin resulted in complete or partial remission in six and eight cases, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/33\">",
"       33",
"      </a>",
"      ]; every patient experienced transient leukopenia with each treatment cycle.",
"     </li>",
"     <li>",
"      In a series of seven patients treated with 15-deoxyspergualin and glucocorticoids, all had complete or partial remission, but prolonged treatment (up to four years) was required [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Careful monitoring of the white blood count is required to avoid excessive leukopenia. The role of this agent remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy for the treatment of airway involvement in GPA has been evaluated in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Nasal and sinus involvement in one instance was treated with two courses of 20 and 26 Gy, administered in 2 Gy fractions given a month apart [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/36\">",
"     36",
"    </a>",
"    ]. Plastic stents were placed in the nasal passages to prevent stenosis due to radiation-induced fibrosis.",
"   </p>",
"   <p>",
"    The use of ionizing radiation for nonmalignant disease is always controversial. Current data do NOT support its use in a systemic disorder like GPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose, myeloablative chemotherapy with stem cell transplantation has been utilized for the treatment of refractory severe vasculitis. There are case reports of successful treatment of vasculitis with renal involvement, including a few patients with GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3321/abstract/37\">",
"     37",
"    </a>",
"    ]. Much more study is required to determine if there is a role for stem cell transplantation in the management of resistant ANCA-associated systemic vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      resistance in patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis (GPA or MPA) is defined as one or both of the following despite therapy for at least one month: progressive decline in renal function (ie, increase in serum creatinine) plus persistence of an active urine sediment (ie, dysmorphic hematuria with or without red cell casts); and persistence or new appearance of extrarenal manifestations of active vasculitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      True",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      resistance must be distinguished from signs of permanent damage induced by previous active disease (eg, an elevated serum creatinine with or without proteinuria in the absence of dysmorphic hematuria), the presence of other diseases, and the development of medication toxicities (eg, infection) that may present with manifestations similar to active disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Unresponsive but not resistant'",
"      </a>",
"      above.)The incidence of cyclophosphamide resistance has been approximately 10 percent in clinical trials, but higher in clinical practice (23 percent in one series). Significant risk factors for resistance include female sex, black ethnicity, and severe kidney disease at presentation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      resistance have a poor prognosis, as 79 percent in one series developed end-stage renal disease at a median of two months after the initiation of therapy. The rate of end-stage renal disease was much lower in patients who attained remission with initial immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient with true",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -resistant active inflammation, the first step is to ensure that the cyclophosphamide regimen has been optimized and, if indicated, plasma exchange has been administered. These issues are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H21#H21\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Role of plasma exchange'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with definitive evidence of persistent active disease involving a major organ, and in whom optimal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      dosing is ineffective or not tolerated, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The suggested dose of rituximab is 375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per week for four weeks given with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000 mg) followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H16198972#H16198972\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rituximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with definitive evidence of persistent active disease involving a major organ, and in whom both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      are ineffective or not tolerated, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The suggested dose of mycophenolate mofetil is 500 mg twice daily which is increased, if there is no response, by 250 mg twice daily every two weeks to a maximum dose of 1500 mg twice daily. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/4\">",
"      Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/5\">",
"      Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/6\">",
"      Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/7\">",
"      Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/8\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/9\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/10\">",
"      De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/11\">",
"      Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/12\">",
"      Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/13\">",
"      Aouba A, Pagnoux C, Bienvenu B, et al. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin Rev Allergy Immunol 2008; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/14\">",
"      Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/15\">",
"      Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005; 20:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/16\">",
"      Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/17\">",
"      Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/18\">",
"      Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/19\">",
"      Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/20\">",
"      Joy MS, Hogan SL, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/21\">",
"      Ibernon M, Poveda R, Vidaller A, et al. Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity. Clin Nephrol 2008; 69:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/22\">",
"      Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/23\">",
"      Kamesh L, Harper L, Savage CO. ANCA-positive vasculitis. J Am Soc Nephrol 2002; 13:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/24\">",
"      Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/25\">",
"      Lockwood CM, Thiru S, Isaacs JD, et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/26\">",
"      Hagen EC, de Keizer RJ, Andrassy K, et al. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995; 43:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/27\">",
"      Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/28\">",
"      Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/29\">",
"      Tuso P, Moudgil A, Hay J, et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 1992; 20:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/30\">",
"      Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/31\">",
"      Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/32\">",
"      Benenson E, Fries JW, Heilig B, et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005; 24:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/33\">",
"      Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/34\">",
"      Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/35\">",
"      Eagleton LE, Rosher RB, Hawe A, Bilinsky RT. Radiation therapy and mechanical dilation of endobronchial obstruction secondary to Wegener's granulomatosis. Chest 1979; 76:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/36\">",
"      Neviani CB, Carvalho Hde A, Hossamu C, et al. Radiation therapy as an option for upper airway obstruction due to Wegener's granulomatosis. Otolaryngol Head Neck Surg 2002; 126:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3321/abstract/37\">",
"      K&ouml;tter I, Daikeler T, Amberger C, et al. Autologous stem cell transplantation of treatment-resistant systemic vasculitis--a single center experience and review of the literature. Clin Nephrol 2005; 64:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3071 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3321=[""].join("\n");
var outline_f3_15_3321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15769692\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cannot take cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Unresponsive but not resistant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF CYCLOPHOSPHAMIDE-RESISTANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Possibly effective therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13942280\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Therapies of unproven efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Anti-TNF-alpha therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anti-T cell antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Intravenous azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - 15-Deoxyspergualin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3071\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3071|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 1A\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 1B\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=related_link\">",
"      Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=related_link\">",
"      Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3322="Outcome and follow-up of diethylstilbestrol (DES) exposed individuals";
var content_f3_15_3322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Elizabeth Hatch, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/15/3322/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/15/3322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diethylstilbestrol (DES) is a nonsteroidal estrogen first synthesized in 1938. It readily crosses the placenta. Exposure to DES during a critical period of organogenesis disorganizes the developing uterine muscle layers; causes maldevelopment of the uterotubal junction; and prevents stratification of the vaginal epithelium and resorption of vaginal glands, resulting in vaginal adenosis. In murine studies, the mechanism for DES-induced adenosis is blocked expression of Trp63 in M&uuml;llerian duct epithelium at epithelial estrogen receptor alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/1\">",
"     1",
"    </a>",
"    ]. DES has also been shown to alter normal programming of the gene families Hox and Wnt, which affect differentiation of the reproductive tract [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DES was initially used for postpartum lactation suppression and treatment of postmenopausal symptoms, but quickly became an accepted intervention for prevention of miscarriage, premature birth, and other pregnancy problems. It is estimated that five million pregnant women worldwide received DES to improve pregnancy outcome. Although clinical trials in the 1950s demonstrated that it was ineffective for prevention of adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/7\">",
"     7",
"    </a>",
"    ], it remained in use until 1971 in the United States and until the early 1980s in some other countries. In 1971, in-utero exposure to DES was linked to the occurrence of vaginal clear cell adenocarcinoma in female offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/8\">",
"     8",
"    </a>",
"    ], which prompted the United States Food and Drug Administration (FDA) to advise against its use in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/9\">",
"     9",
"    </a>",
"    ]. Subsequently, other health effects, such as pregnancy complications and male genitourinary tract abnormalities, were also linked to in-utero DES exposure. DES is no longer commercially available for human use in North America.",
"   </p>",
"   <p>",
"    DES remains the only firmly established transplacental carcinogen in humans. Because of this risk, it is important to continue to monitor exposed offspring and their mothers for long-term health effects. DES is also important as the model agent for endocrine disrupting chemicals and their effects on fetal development and adult health [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Aberrant DNA methylation has been proposed as a molecular mechanism whereby endocrine disruptors such as DES regulate developmental programming [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WOMEN WHO RECEIVED DES DURING PREGNANCY (DES MOTHERS)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565946343\">",
"    <span class=\"h2\">",
"     Breast cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a slightly increased incidence of breast cancer among women who were prescribed DES during pregnancy (DES mothers) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. The largest and most comprehensive study on this topic compared long-term cancer risk in a database of 3844 women prescribed DES during pregnancy to an unexposed comparison group of 3716 women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/14\">",
"     14",
"    </a>",
"    ]. Women who took DES had a statistically significant increased risk of breast cancer (relative risk [RR] 1.27, 95% CI 1.07-1.52); looked at in another way, their lifetime risk of breast cancer increased from 1 in 8 (about 12 percent) to 1 in 6 (about 17 percent). There was no evidence of an interaction between the use of postmenopausal hormone therapy and DES in relation to breast cancer risk, and the risk did not increase over time. The higher risk did not appear to be due to inherent characteristics of the women who were given DES (ie, women with pregnancy problems) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565955473\">",
"    <span class=\"h2\">",
"     Other cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who were prescribed DES during pregnancy are",
"    <strong>",
"     not",
"    </strong>",
"    at increased risk of ovarian or endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/13-18\">",
"     13-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565946350\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large database described above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/19\">",
"     19",
"    </a>",
"    ] found no statistically significant increase in mortality rates among women prescribed DES compared with unexposed women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All cause mortality (RR 1.06, 95% CI 0.98-1.16)",
"     </li>",
"     <li>",
"      Mortality from cerebrovascular disease (RR 1.08, 95% CI 0.78-1.47)",
"     </li>",
"     <li>",
"      Mortality from cardiovascular disease (RR 0.98, 95% CI 0.83-1.16)",
"     </li>",
"     <li>",
"      Cancer mortality (all types) (RR 1.07, 95% CI 0.94-1.23)",
"     </li>",
"     <li>",
"      Breast cancer mortality (RR 1.27, 95% CI 0.96-1.69). This increase reflects an increase in breast cancer occurrence in DES-exposed mothers (RR 1.27, 95% CI 1.07-1.52) (see",
"      <a class=\"local\" href=\"#H565946343\">",
"       'Breast cancer risk'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WOMEN EXPOSED TO DES IN-UTERO (DES DAUGHTERS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-utero exposure to diethylstilbestrol (DES) has been associated with several potential risks in female offspring (DES daughters):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cervicovaginal clear cell adenocarcinoma (CCA)",
"     </li>",
"     <li>",
"      Congenital anomalies and epithelial changes of the reproductive tract",
"     </li>",
"     <li>",
"      Subfertility and adverse pregnancy outcomes",
"     </li>",
"     <li>",
"      Earlier age at menopause",
"     </li>",
"     <li>",
"      Breast cancer",
"     </li>",
"     <li>",
"      Cervical intraepithelial neoplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clear cell adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES daughters have a 40-fold increase in risk of CCA of the vagina and cervix compared to unexposed women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, the cumulative lifetime incidence of CCA is very low, estimated to be 1 case per 1000 to 2000 DES-exposed daughters. A registry established to track cases of cervical and vaginal CCA worldwide included 760 cases as of 2007; two-thirds of these cases were women exposed to DES in-utero [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of DES-associated CCA have been diagnosed among females in their late teens and twenties, with a range of 7 to 48 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/23\">",
"     23",
"    </a>",
"    ]. By comparison, most cases of CCA among non-exposed women occur postmenopausally, although early and late age peaks have been reported in non-exposed women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data to allow clear conclusions about the upper age limit for the diagnosis of DES-associated CCA, especially regarding late risk in DES daughters after menopause; a possible increase in incidence of DES-associated CCA at age &ge;40&nbsp;years has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. For this reason, DES daughters should be screened for CCA throughout their lives (see",
"    <a class=\"local\" href=\"#H19311264\">",
"     'DES daughters'",
"    </a>",
"    below). Oncogenic human papillomaviruses (HPVs) are unlikely to be a co-factor in the development of CCA of the vagina or cervix; however, if there is an association, it is less than that reported for squamous or non-clear-cell adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of CCA may include abnormal vaginal bleeding, abnormal vaginal discharge, or a gross red, fleshy lesion on the vagina or cervix. Ninety percent of cases of CCA related to DES have been diagnosed at Stage 1 or 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/27\">",
"     27",
"    </a>",
"    ]. Survival rates at these stages are good (80 to 90 percent), but recurrences as late as 20 years following diagnosis have been documented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link&amp;anchor=H7#H7\">",
"     \"Vaginal cancer\", section on 'Adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565955742\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data on risk of breast cancer in women exposed to DES in-utero are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/25,28,29\">",
"     25,28,29",
"    </a>",
"    ]. There is no evidence of a statistically increased risk of breast cancer before age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/30\">",
"     30",
"    </a>",
"    ]. An increased risk in women &ge;40 years of age exposed to DES in-utero was observed in a prospective cohort study from the US (3.9 versus 2.2 percent, hazard ratio [HR] 1.82; 95% CI 1.04-3.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ], but not in another similar but larger study from the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors could explain these discordant findings, including chance. There were only 102 incident invasive breast cancers in the US study and 165 in the Dutch study. The risk of breast cancer in DES daughters in the Dutch study may have been attenuated because of misclassification of exposure status since DES exposure was not as rigorously confirmed as it was in the US study. Bias might result if the development of breast cancer (particularly over the age of 40 years) selectively affected exposed and unexposed women who were lost to follow-up. The age distribution in the two studies was slightly different; the Dutch cohort was younger than the US cohort. The Dutch study compared breast cancer risk in DES-exposed women with the risk in the general population, whereas DES daughters might differ from the general population with respect to breast cancer risk factors.",
"   </p>",
"   <p>",
"    Continued surveillance is warranted to determine whether the increase in breast cancer risk continues as these women age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565955984\">",
"    <span class=\"h2\">",
"     Other cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence for an increased risk of other cancer sites among DES-exposed daughters, but this may be due to the relatively small numbers of exposed daughters in existing cohort studies of DES. One study found no overall increase in risk of all cancers combined, or individual cancers, except for breast cancer and CCA, when comparing rates in the exposed daughters to expected rates based on the Surveillance, Epidemiology and End Results (SEER) population (standardized incidence rate ratio 1.01, 95% CI 0.94-1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/20\">",
"     20",
"    </a>",
"    ]. Another study found an increase in melanoma among exposed daughters before but not after age 40 years (before age 40 years: standardized incidence ratio [SIR] 1.59, 95% CI 1.08&ndash;2.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/25\">",
"     25",
"    </a>",
"    ]. A limitation of this study is that DES exposure was not documented by medical records. Continued follow-up of these cohorts should provide more evidence on other cancer sites, such as Fallopian tube cancer, as the cohort&rsquo;s age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reproductive tract abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital reproductive tract anomalies associated with in-utero DES exposure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterus &mdash;Hypoplastic uterus, T-shaped uterine cavity (",
"      <a class=\"graphic graphic_figure graphicRef68607 graphicRef80368 graphicRef62485 \" href=\"UTD.htm?39/29/40405\">",
"       figure 1A-C",
"      </a>",
"      ), constrictions and adhesions of the endometrial cavity",
"     </li>",
"     <li>",
"      Cervix &mdash; Hypoplasia, collar, hood, polyps, ectropion (adenosis of the ectocervix)",
"     </li>",
"     <li>",
"      Vagina &mdash; Ridge, transverse septa, vaginal adenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3247811\">",
"    <span class=\"h3\">",
"     Uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine changes (hypoplasia, abnormalities of the endometrial cavity) in nonpregnant women are likely to be asymptomatic, although one study found a decrease in the duration and amount of menstrual bleeding, which may have been related to the uterine changes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/31\">",
"     31",
"    </a>",
"    ]. Cycle length was not affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3248013\">",
"    <span class=\"h3\">",
"     Cervix and vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross cervical abnormalities (hypoplasia, collar, hood, polyps) are visualized in about 20 percent of exposed women. In one study, approximately 75 percent of DES-exposed women had an abnormal hysterosalpingogram; however, this estimate is likely to be high since it was derived from a population undergoing evaluation for infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/32\">",
"     32",
"    </a>",
"    ]. Vaginal abnormalities (ridge, septa) are less common. Reproductive tract anomalies may be associated with a higher risk of pregnancy complications. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pregnancy issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3248029\">",
"    <span class=\"h3\">",
"     Adenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical and vaginal adenoses are defined as the development of columnar epithelium of the ectocervix and vagina rather than normal squamous epithelium. The columnar epithelium may cover the surface or form glands within the stromal wall. As a result, the squamocolumnar junction, which is normally near the external os or in the endocervical canal, can be in the vagina. DES is one cause but not the only cause of adenosis; it may be related to other hormones or environmental chemicals (endocrine disrupters) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large cohort study of DES-exposed women (the National Cooperative Diethylstilbestrol Adenosis [DESAD] project), one-third of these women had vaginal and cervical adenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/33\">",
"     33",
"    </a>",
"    ]. The prevalence of adenoses in DES daughters has been reported as high as 91 percent in some studies compared with 4 percent in non-DES-exposed controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenosis often regresses over time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/34\">",
"     34",
"    </a>",
"    ], thus treatment is unnecessary except in rare women who are symptomatic. Although benign, adenosis is considered a precursor of CCA; the factors that promote malignant transformation of adenosis to CCA are not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3248058\">",
"    <span class=\"h3\">",
"     Vulva",
"    </span>",
"    &nbsp;&mdash;&nbsp;No changes in the vulva associated with DES exposure have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Earlier menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;A longitudinal study of women exposed to DES in-utero found that they reached natural menopause slightly earlier than unexposed women (51.5 versus 52.2 years) and were 1.5 times more likely to experience natural menopause at any given age compared to unexposed women of the same age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/35\">",
"     35",
"    </a>",
"    ]. In a subset of the study cohort that had complete information on the cumulative dose of DES given during pregnancy, there were significant dose-response effects, eg, a two-fold higher risk of menopause in women exposed to the highest dose level (&gt;10 grams). In the same study population, DES-exposed women (n = 3393) were more than twice as likely to have an early age at natural menopause (&lt;45 years of age) as unexposed women (n = 1682) (5.1 versus 1.7 percent; HR 2.35, 95% CI 1.67-3.31) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ]. Animal studies have reported reductions in ovarian follicles among DES-exposed mice, which support the biologic plausibility of these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of women exposed to DES in-utero do not have difficulty becoming pregnant, but DES exposure appears to confer a higher risk of subfertility. The largest comprehensive study of 3769 DES-exposed and 1654 unexposed women found that DES-exposed women were twice as likely to experience infertility (attempting but failing to conceive over a period of &ge;12 months) compared to unexposed women (cumulative risk to age 45 years: 33.3 percent versus 15.5 percent; HR 2.37, 95% CI 2.05-2.75) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ]. The infertility risk was highest for women with vaginal epithelial changes at a young age, a marker of high DES dose and exposure early in gestation.",
"   </p>",
"   <p>",
"    Infertility does not appear to be due to an increased prevalence of ovulatory or hormonal problems in DES-exposed women, but appears related to uterine and tubal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/36\">",
"     36",
"    </a>",
"    ]. Endometriosis may also be a factor. A large prospective cohort study of nurses found that the risk of endometriosis was increased by 80 percent among women who reported that they had been exposed to DES prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES daughters have an increased risk of ectopic pregnancy. This was illustrated by a prospective cohort study of 2692 DES-exposed and 1293 unexposed women who had ever been pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ]. After adjustment for number of pregnancies, DES-exposed women had an 11.7 percent excess risk of ectopic pregnancy (cumulative risk to age 45 years: 14.6 versus 2.9 percent; HR 3.72, 95% CI 2.58-5.38). The higher risk of ectopic pregnancy is most likely related to tubal and uterine abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DES daughters should be evaluated for ectopic pregnancy early in the first trimester. A definitive diagnosis of intrauterine pregnancy can be made 4.5 to 6 weeks after the last menstrual period and when the serum human chorionic gonadotropin (hCG) concentration is at least 1000 to 1500",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pregnancy loss and preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women exposed to DES in-utero also have higher risks of miscarriage and premature birth, possibly related to the structural abnormalities of the",
"    <span class=\"nowrap\">",
"     cervix/uterus",
"    </span>",
"    seen in DES daughters. A prospective cohort study compared the pregnancy outcome of 2692 women exposed to DES in-utero to 1293 unexposed controls who had ever been pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ]. DES exposure was associated with increased cumulative risk to age 45 years of spontaneous abortion (50.3 versus 38.6 percent; HR 1.64, 95% CI 1.42-1.88), preterm delivery (53.3 versus 17.8 percent; HR 4.68, 95% CI 3.74-5.86), and loss of second-trimester pregnancy (16.4 versus 1.7 percent; HR 3.77, 95% CI 2.56-5.54). Although the risk of preterm birth was increased, most DES daughters have delivered at term in their first pregnancy (64 versus 85 percent of unexposed women) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk of pregnancy complications appears to be higher in women with a reproductive tract abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28,40,41\">",
"     28,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of cervical insufficiency leading to midtrimester pregnancy loss or preterm birth is not eliminated by either a normal cervical appearance or a prior term delivery in the DES-exposed woman. We suggest cervical surveillance with transvaginal ultrasound, which may identify women at risk of",
"    <span class=\"nowrap\">",
"     preterm/previable",
"    </span>",
"    birth at a time when intervention is possible. Management of these pregnancies depends on the woman&rsquo;s obstetric history and findings on ultrasound examination, and is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Secondary sex ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study that evaluated the secondary sex ratio of offspring born to DES-exposed women did not find a significant effect in exposed women (odds ratio [OR] 1.05, 95% CI 0.95-1.17) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/42\">",
"     42",
"    </a>",
"    ]. However, when the results were evaluated according to dose and timing of first exposure to DES, there was an increase in the proportion of male births among women exposed early in gestation to higher doses of DES (OR 1.24, 95% CI 1.04-1.48 for first trimester exposure to 5 or more grams of DES) compared with no exposure. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in-utero DES exposure appears to be associated with an increase in risk of preeclampsia (cumulative risk to age 45 years: 26.4 versus 13.7 percent; HR 1.42, 95% CI 1.07-1.89 adjusted for number of births) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7869954\">",
"    <span class=\"h3\">",
"     Stillbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-utero DES exposure appears to be associated with an increase in risk of stillbirth (cumulative risk to age 45 years: 8.9 versus 2.6 percent; HR 2.45, 95% CI 1.33-4.54) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ]. However, there were only 70 stillbirths in the entire cohort of DES-exposed and unexposed women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cervical squamous intraepithelial lesions (CIN) and cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of high-grade squamous intraepithelial lesions (HSIL) is increased almost two-fold in DES-exposed daughters (cumulative risk to age 55 years: cervical intraepithelial neoplasia [CIN] 6.9 versus 3.4 percent; HR 2.28, 95% CI 1.59-3.27) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"     28",
"    </a>",
"    ]. The excess risk may be due to an increase in the size of the cervical transformation zone, leading to greater susceptibility to HPV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study from the Netherlands found that the prevalence of cervical cancer was approximately three-fold higher than expected among DES-exposed daughters, but the study was limited by small numbers and poor documentation of DES exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Autoimmune diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The weight of evidence in humans suggests that autoimmune diseases are not more common among DES-exposed offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. One cohort study reported an increased risk of confirmed cases of rheumatoid arthritis in women under 45 years, but this was counterbalanced by a reduced risk among exposed women 45 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/46\">",
"     46",
"    </a>",
"    ]. Long-term follow-up and further research as the DES-exposed population ages are needed, as animal studies have indicated that DES can affect immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Psychological disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten reports have evaluated psychosexual development in DES-exposed offspring compared with a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/48\">",
"     48",
"    </a>",
"    ]. Although some reported an increased prevalence of depression, anxiety, and anorexia nervosa, these studies were mostly based upon small numbers and had methodologic flaws. One large series including 2684 males and 5686 females reported no association between in-utero DES-exposure and self-reported mental illness or sexual orientation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Benign gynecological tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of uterine leiomyomas and ovarian cysts does not appear to be increased in DES-exposed offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/50\">",
"     50",
"    </a>",
"    ]. There may be an increase in paraovarian cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MEN EXPOSED TO DES IN-UTERO (DES SONS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health effects of in-utero diethylstilbestrol (DES) exposure among male offspring (DES sons) have not been studied as extensively as in females.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genitourinary abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest study of genitourinary abnormalities in DES sons included 1157 males prenatally exposed to DES [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/51\">",
"     51",
"    </a>",
"    ]. Compared to 1038 unexposed males, DES-exposed males were at increased risk of epididymal cysts (RR 2.4, 95% CI 1.5-4.3), cryptorchidism (RR 1.9, 95% CI 1.1-3.4), and testicular",
"    <span class=\"nowrap\">",
"     inflammation/infection",
"    </span>",
"    (RR 2.5, 95% CI 1.5-4.4). Exposure prior to 11 weeks of gestation was associated with the highest risk. There was no increase in other genitourinary abnormalities (varicocele, structural abnormalities of the penis, urethral stenosis, benign prostatic hypertrophy, or",
"    <span class=\"nowrap\">",
"     inflammation/infection",
"    </span>",
"    of the prostate, urethra, or epididymis).",
"   </p>",
"   <p>",
"    A long-term follow-up study of male offspring exposed to large doses of DES during a randomized trial at the University of Chicago in the 1950s found that 15 percent of DES sons reported a genitourinary abnormality compared to only 5 percent of unexposed sons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/52\">",
"     52",
"    </a>",
"    ]. As above, abnormalities occurred more frequently among males who were exposed before 11 weeks of gestation. DES sons had no impairment of sexual function, as measured by frequency of intercourse or reported episodes of decreased libido.",
"   </p>",
"   <p>",
"    However, others have not observed an increased risk of reproductive abnormalities in DES sons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies report no impairment of fertility in men with in-utero DES exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/52,53,55-58\">",
"     52,53,55-58",
"    </a>",
"    ]. As an example, in the large placebo controlled study discussed above, DES sons (with or without genital malformations) had no impairment of fertility when assessed in terms of whether they had ever impregnated a women, age at the birth of their first child, average number of children, medical diagnosis of a fertility problem, or length of time to conception in the most recent pregnancy of the female partner [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Testicular and prostate cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of DES in the development of testicular cancer is a controversial subject. Cryptorchidism (a risk factor for testicular cancer) has been reported in the sons of women exposed to DES or oral estrogens during pregnancy, and some studies reported an association between DES or other exogenous hormone exposure during pregnancy and testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. More rigorous studies have failed to prove, but have not definitely excluded, an epidemiological link between DES exposure and testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/53,63-66\">",
"     53,63-66",
"    </a>",
"    ]. Assessment of DES exposure in most of these studies was based upon maternal self-report many years after the pregnancy, and may have been inaccurate. The number of cases analyzed was small, further limiting the power of the studies. In the only cohort study with medical record confirmation of exposure status, the testicular cancer incidence rate in exposed sons was approximately three times that of the unexposed, but was based on only six exposed and two unexposed cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence of an association between DES exposure in humans and prostate cancer, but DES sons are now entering the age groups when prostate cancer incidence increases. Studies in mice have demonstrated an association between DES exposure and an increased rate of rete testis cancer and prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/67\">",
"     67",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     THIRD GENERATION EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few human studies on the transgenerational effects of diethylstilbestrol (DES) have been published. There is no strong evidence of adverse effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined 28 DES third generation daughters in whom 61 percent of their mothers had well-documented genital tract changes associated with DES [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/68\">",
"       68",
"      </a>",
"      ]. No lower genital tract DES-associated abnormalities were found in these daughters, who ranged in age from 15 to 28 years.",
"     </li>",
"     <li>",
"      Another study reported the mean age at menarche was 12.6 years in both DES-exposed and unexposed third generation daughters, but daughters of the exposed women attained menstrual regularization later (mean age of 16.2 years versus 15.8 years), and were more likely to report irregular menstrual periods (OR 1.54, 95% CI 1.02-2.32) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cohort study from the Netherlands reported a higher prevalence of hypospadias in DES third generation sons [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/70\">",
"       70",
"      </a>",
"      ]. These results were based on a small number of cases, but were confirmed in a subsequent retrospective study from France [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/71\">",
"       71",
"      </a>",
"      ]. In contrast, a subsequent larger study that documented in-utero DES exposure did not find a statistically significant association between DES and hypospadias in the third generation (OR 1.7, 95% CI 0.4-6.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control study from the Netherlands observed an association between esophageal",
"      <span class=\"nowrap\">",
"       atresia/tracheoesophageal",
"      </span>",
"      fistula in third generation offspring and maternal exposure to DES in-utero [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/73\">",
"       73",
"      </a>",
"      ]. In addition, a survey of women participating in a large, multicenter study of prenatal DES exposure in the United States reported an increase in birth defects among third generation sons (OR 1.53, 95% CI 1.04-2.23) and daughters (OR 2.35, 95% CI 1.44-3.82) compared to unexposed controls [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/74\">",
"       74",
"      </a>",
"      ]. Third generation daughters appeared to have an excess of congenital heart disease. Reporting bias may have played a role in these findings.",
"     </li>",
"     <li>",
"      No clear increase in cancer risk in third generation males and females has been demonstrated. A possible increase in ovarian tumors in third generation females was observed; however, this was based upon only three cases in the exposed group and is thus uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Animal studies have found increased rates of tumors, including uterine, ovarian, and rete testis tumors, among third generation mice exposed to DES [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The incidence of tumors was low, and the tumors tended to occur in older animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565948378\">",
"    <span class=\"h1\">",
"     HEALTH CARE OF DES-EXPOSED INDIVIDUALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to receive appropriate health care and follow-up, women who took diethylstilbestrol (DES) in pregnancy should inform their children of in-utero exposure and all exposed individuals (men and women) should inform their health care providers of their exposure.",
"   </p>",
"   <p>",
"    DES-exposed women may be concerned about using hormonal therapies, but there is no evidence that hormonal contraception, ovulation induction agents, or postmenopausal estrogen therapy confers a higher risk in DES daughters than in unexposed women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/14,78\">",
"     14,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3248243\">",
"    <span class=\"h2\">",
"     Screening and surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally agree with American Cancer Society (ACS) and National Cancer Institute (NCI) recommendations for follow-up of DES-exposed individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. These recommendations reflect expert opinion based on the data described above. Where the recommendations are vague, we have provided our approach to these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19311257\">",
"    <span class=\"h3\">",
"     DES mothers",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES mothers should have regular medical check-ups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in all women, recommendations for initiation, method, and frequency of breast cancer screening should be based on patient-specific composite risk factors, including DES exposure. In the absence of any other risk factor for breast cancer, the lifetime risk of breast cancer in DES mothers is estimated to be about 17 percent, which is considered mildly to moderately elevated (where low risk is &lt;15 percent and high risk is &gt;20 to 25 percent lifetime risk). &nbsp;A detailed discussion of initiation, frequency, and modalities for breast cancer screening based on patient-specific factors can be found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H48#H48\">",
"       \"Screening for breast cancer\", section on 'Mild to moderately increased lifetime breast cancer risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DES mothers have no increased risk for cervical, vaginal, or other cancers. They should be screened for cervical cancer according to standard guidelines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"       \"Screening for cervical cancer: Rationale and recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19311264\">",
"    <span class=\"h3\">",
"     DES daughters",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES-exposed daughters should have a yearly gynecologic examination. No upper age limit for examination has been determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link\">",
"     \"The gynecologic history and pelvic examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NCI states: &ldquo;The appropriate interval for follow-up examination of DES-exposed daughters is determined on an individual basis. For most patients with non-staining epithelial or structural changes in the vagina or cervix, or with microscopic changes such as adenosis, yearly examinations are adequate. Before a diagnosis of intraepithelial neoplasia can be confirmed, all abnormal cytologic and biopsy specimens should be reviewed by a pathologist who is thoroughly familiar with changes in samples from DES-exposed women, particularly because immature squamous metaplasia is often difficult to distinguish from intraepithelial neoplasia. Important steps in the follow-up examination include palpation, inspection, and cytologic tests. Attention should focus on the changes observed since the initial evaluation. Cervical and vaginal cytologic examination is presently performed each year. Women should be asked about interval bleeding or abnormal vaginal discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/15/3322/abstract/82\">",
"     82",
"    </a>",
"    ].&rdquo;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The components of the yearly gynecologic examination vary and are based on patient-specific factors, such as history of abnormal cytology and",
"      <span class=\"nowrap\">",
"       presence/absence",
"      </span>",
"      of adenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Examination of genitalia and clinical breast examination are performed yearly.",
"     </li>",
"     <li>",
"      Speculum examination is performed yearly. Rotate the speculum to allow inspection of the entire epithelial surface of the vagina and cervix. Adenosis may appear red and granular, while squamous metaplasia may be indistinguishable from normal squamous epithelium without iodine staining. Clear cell carcinoma of the cervix or vagina usually presents as a polypoid mass. Vaginal neoplasms most often occur on the anterior wall.",
"     </li>",
"     <li>",
"      The optimum frequency and upper age limit for obtaining cervicovaginal cytology in DES daughters is unknown. No studies have evaluated when cervical cancer screening can be discontinued; there is a theoretical concern that there may be a second peak in related cancers as the cohort ages. There are no recommendations from expert groups regarding an upper age limit. Therefore, until further data are available, we currently continue surveillance screening indefinitely. In the absence of any data to guide practice, we suggest yearly cervical and vaginal cytology (without HPV testing) through age 70 years and then every three years as long as the woman is a candidate for intervention if cancer is diagnosed. In women who have undergone hysterectomy, a vaginal specimen is obtained.",
"      <br/>",
"      <br/>",
"      This recommendation is based on the following factors: unlike squamous cell carcinoma (1) oncogenic HPV is probably not a factor in development of clear cell adenocarcinoma (CCA), (2) CCA has no nonmalignant precursor (eg, high-grade squamous intraepithelial lesions [HSIL], atypical glandular cells) detectable by cytology, thus allowing intervention at a premalignant state, and (3) CCA may be palpable before it is detectable by cytology. Furthermore, there is no evidence that DES daughters of advanced age are at higher risk of developing CCA than non-exposed women of advanced age, and screening for CCA is not standard practice for non-DES-exposed women.",
"      <br/>",
"      <br/>",
"      The lower age limit for initiating screening is now irrelevant since the youngest DES daughters worldwide are over 21 years of age, the standard age for initiating screening in low risk women.",
"      <br/>",
"      <br/>",
"      Cytology specimens should be obtained from the cervix (brush for endocervical canal, spatula for transformation zone) and four quadrants (circumference) of the upper one-third of the vagina (spatula). All of the specimens can be placed on one",
"      <span class=\"nowrap\">",
"       slide/container.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"       \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Unlike squamous cell cancer, CCA does not have a precursor (eg, HSIL) detectable by cervical and vaginal cytology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Iodine staining (Lugol&rsquo;s solution: 2.5% iodine with 5% iodide in water) of the cervix and vagina is performed to confirm the boundaries of epithelial changes observed by colposcopy or to determine the boundaries of changes when there has been no colposcopy, but is not recommended as a routine screening tool.",
"     </li>",
"     <li>",
"      Colposcopy may be used to assess the extent of gross vaginal and cervical epithelial change and is often indicated to further evaluate abnormal cytology. Evaluation and management of abnormal cervical cytology is the same for DES-exposed and unexposed women, and is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Management\"",
"      </a>",
"      .) Colposcopy is not recommended as a routine screening tool. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"       \"Colposcopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Biopsy is indicated for indurated or granular areas, palpable nodules or masses, or discrete areas that appear to be of a different color or texture than the surrounding tissue. Random sampling is not recommended.",
"     </li>",
"     <li>",
"      Bimanual pelvic and rectal examination should be performed yearly. Palpation of the entire length of the vagina, including the fornices, is essential for detection of CCA and may be the only way to identify these lesions; cytology will be negative if tumor cells have not penetrated the vaginal epithelium. Areas of thickening or induration or nodules should raise suspicion for CCA and should lead to sampling by biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in all women, recommendations for initiation, method, and frequency of breast cancer screening should be based on patient-specific composite risk factors, including DES exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"       \"Screening for breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19311271\">",
"    <span class=\"h3\">",
"     DES sons",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No special screenings or tests are recommended. In the general population, there is no evidence that routine screening for testicular cancer through periodic clinical examinations or self-examinations improves health outcomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28261?source=see_link\">",
"       \"Screening for testicular cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Symptomatic men should report their symptoms (eg, painful or tender mass, testicular firmness, scrotal heaviness, hematuria) to their health care provider. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565948585\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Centers for Disease Control and Prevention (CDC)",
"      <br/>",
"      1-800-232-4636 (toll free)",
"      <br/>",
"      <br/>",
"      <a class=\"external\" href=\"file://cdcinfo@cdc.gov/\">",
"       cdcinfo@cdc.gov",
"      </a>",
"      <br/>",
"      <a class=\"external\" href=\"file://www.cdc.gov/des\">",
"       file://www.cdc.gov/des",
"      </a>",
"     </li>",
"     <li>",
"      Registry for Research on Hormonal Transplacental Carcinogenesis (Clear Cell Cancer Registry)",
"      <br/>",
"      University of Chicago, Department of Obstetrics and Gynecology",
"      <br/>",
"      <br/>",
"      <a class=\"external\" href=\"file://obgyn.bsd.uchicago.edu/registry.html\">",
"       file://obgyn.bsd.uchicago.edu/registry.html",
"      </a>",
"     </li>",
"     <li>",
"      Resources that provide information and support for individuals who were exposed to DES:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      DES Action USA (",
"      <a class=\"external\" href=\"file://www.desaction.org/\">",
"       www.desaction.org",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      DES Cancer Network (",
"      <a class=\"external\" href=\"file://www.descancer.org/\">",
"       www.descancer.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who took diethylstilbestrol (DES) during pregnancy should inform their health care providers and their offspring. Offspring should also inform their health care providers of in-utero exposure. (See",
"      <a class=\"local\" href=\"#H565948378\">",
"       'Health care of DES-exposed individuals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565952241\">",
"    <span class=\"h2\">",
"     Women who received DES during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Women who received DES during pregnancy (DES mothers)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who received DES during pregnancy have a slightly increased risk of developing breast cancer (RR 1.3) (see",
"      <a class=\"local\" href=\"#H565946343\">",
"       'Breast cancer risk'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      We agree with National Cancer Institute (NCI) and American Cancer Society (ACS) recommendations that women who took DES during pregnancy follow current guidelines for initiation, method, and frequency of breast cancer screening and prevention for their age and risk group. (See",
"      <a class=\"local\" href=\"#H19311257\">",
"       'DES mothers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"       \"Screening for breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565952421\">",
"    <span class=\"h2\">",
"     Women exposed to DES in-utero",
"    </span>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Women exposed to DES in-utero (DES daughters)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women exposed to DES in-utero appear to be at increased risk for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervicovaginal clear cell adenocarcinoma (CCA) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clear cell adenocarcinoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Congenital anomalies and epithelial changes of the reproductive tract",
"      <strong>",
"      </strong>",
"      (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Reproductive tract abnormalities'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Infertility, ectopic pregnancy, pregnancy loss, preterm birth (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Infertility'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Ectopic pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy loss and preterm birth'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cervical intraepithelial neoplasia (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Cervical squamous intraepithelial lesions (CIN) and cancer'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Earlier menopause (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Earlier menopause'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data on increased risk of breast cancer in women exposed to DES in-utero are conflicting. (See",
"      <a class=\"local\" href=\"#H565955742\">",
"       'Breast cancer'",
"      </a>",
"      above.) We agree with NCI and ACS recommendations that women who took DES during pregnancy should follow current guidelines for initiation, method, and frequency of breast cancer screening for their age and risk group. (See",
"      <a class=\"local\" href=\"#H19311264\">",
"       'DES daughters'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"       \"Screening for breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women exposed to DES in-utero should undergo a yearly gynecologic examination. This examination should include visual inspection and palpation of the entire vagina for abnormal growths. We suggest yearly cytological cervical and vaginal cancer screening through age 70 years, and then every three years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). All four quadrants of the upper vagina should be sampled and sent for analysis, in addition to the cervical specimen. (See",
"      <a class=\"local\" href=\"#H19311264\">",
"       'DES daughters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy in DES daughters should be monitored closely because of the increased risk for ectopic pregnancy, miscarriage, and preterm birth. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565952954\">",
"    <span class=\"h2\">",
"     Men exposed to DES in-utero",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Males exposed to DES in-utero have a higher prevalence of benign epididymal cysts, cryptorchidism, and testicular",
"      <span class=\"nowrap\">",
"       inflammation/infection.",
"      </span>",
"      It is unclear whether they have any increased risk of",
"      <span class=\"nowrap\">",
"       testicular/prostate",
"      </span>",
"      cancer. They do not appear to have an increased frequency of infertility. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Men exposed to DES in-utero (DES sons)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No special screenings or tests are recommended. In the general population, there is no evidence that routine screening for testicular cancer through periodic clinical examinations or self-examinations improves health outcomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28261?source=see_link\">",
"       \"Screening for testicular cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Symptomatic men should report their symptoms (eg, painless or tender mass, testicular firmness, scrotal heaviness, hematuria) to their health care provider. (See",
"      <a class=\"local\" href=\"#H19311271\">",
"       'DES sons'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565952963\">",
"    <span class=\"h2\">",
"     Third generation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no strong evidence that the grandchildren of women who received DES during pregnancy are at increased risk of adverse effects. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Third generation effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/1\">",
"      Kurita T, Mills AA, Cunha GR. Roles of p63 in the diethylstilbestrol-induced cervicovaginal adenosis. Development 2004; 131:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/2\">",
"      Maydl R, Newbold RR, Metzler M, McLachlan JA. Diethylstilbestrol metabolism by the fetal genital tract. Endocrinology 1983; 113:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/3\">",
"      Miller C, Degenhardt K, Sassoon DA. Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat Genet 1998; 20:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/4\">",
"      Pavlova A, Boutin E, Cunha G, Sassoon D. Msx1 (Hox-7.1) in the adult mouse uterus: cellular interactions underlying regulation of expression. Development 1994; 120:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/5\">",
"      Taylor HS, Vanden Heuvel GB, Igarashi P. A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod 1997; 57:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/6\">",
"      Woodruff TJ, Carlson A, Schwartz JM, Giudice LC. Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility: executive summary. Fertil Steril 2008; 89:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/7\">",
"      Bamigboye AA, Morris J. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. Cochrane Database Syst Rev 2003; :CD004353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/8\">",
"      Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284:878.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Bulletin:Diethylstilbestrol contraindicated in pregnancy. US Department of Health, Education, and Welfare. Washington, DC, 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/10\">",
"      Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology 2006; 147:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/11\">",
"      Ma L. Endocrine disruptors in female reproductive tract development and carcinogenesis. Trends Endocrinol Metab 2009; 20:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/12\">",
"      Bromer JG, Wu J, Zhou Y, Taylor HS. Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming. Endocrinology 2009; 150:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/13\">",
"      Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 1995; 122:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/14\">",
"      Titus-Ernstoff L, Hatch EE, Hoover RN, et al. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Br J Cancer 2001; 84:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/15\">",
"      Hadjimichael OC, Meigs JW, Falcier FW, et al. Cancer risk among women exposed to exogenous estrogens during pregnancy. J Natl Cancer Inst 1984; 73:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/16\">",
"      Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. Further follow-up. JAMA 1993; 269:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/17\">",
"      Greenberg ER, Barnes AB, Resseguie L, et al. Breast cancer in mothers given diethylstilbestrol in pregnancy. N Engl J Med 1984; 311:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/18\">",
"      Calle EE, Mervis CA, Thun MJ, et al. Diethylstilbestrol and risk of fatal breast cancer in a prospective cohort of US women. Am J Epidemiol 1996; 144:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/19\">",
"      Titus-Ernstoff L, Troisi R, Hatch EE, et al. Mortality in women given diethylstilbestrol during pregnancy. Br J Cancer 2006; 95:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/20\">",
"      Troisi R, Hatch EE, Titus-Ernstoff L, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer 2007; 121:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/21\">",
"      Melnick S, Cole P, Anderson D, Herbst A. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 1987; 316:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/22\">",
"      Laronda MM, Unno K, Butler LM, Kurita T. The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero. Differentiation 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Registry for Research on Hormonal Transplacental Carcinogenesis (obgyn.bsd.uchicago.edu/registry.html). Accessed October 5, 2010",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/24\">",
"      Hanselaar A, van Loosbroek M, Schuurbiers O, et al. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer 1997; 79:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/25\">",
"      Verloop J, van Leeuwen FE, Helmerhorst TJ, et al. Cancer risk in DES daughters. Cancer Causes Control 2010; 21:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/26\">",
"      Waggoner SE, Anderson SM, Van Eyck S, et al. Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix. Obstet Gynecol 1994; 84:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/27\">",
"      Herbst AL, Anderson D. Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol. Semin Surg Oncol 1990; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/28\">",
"      Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med 2011; 365:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/29\">",
"      Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol 2007; 8:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/30\">",
"      Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/31\">",
"      Hornsby PP, Wilcox AJ, Weinberg CR, Herbst AL. Effects on the menstrual cycle of in utero exposure to diethylstilbestrol. Am J Obstet Gynecol 1994; 170:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/32\">",
"      Kaufman RH, Adam E, Noller K, et al. Upper genital tract changes and infertility in diethylstilbestrol-exposed women. Am J Obstet Gynecol 1986; 154:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/33\">",
"      Robboy SJ, Kaufman RH, Prat J, et al. Pathologic findings in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) project. Obstet Gynecol 1979; 53:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/34\">",
"      Noller KL, Townsend DE, Kaufman RH, et al. Maturation of vaginal and cervical epithelium in women exposed in utero to diethylstilbestrol (DESAD Project). Am J Obstet Gynecol 1983; 146:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/35\">",
"      Hatch EE, Troisi R, Wise LA, et al. Age at natural menopause in women exposed to diethylstilbestrol in utero. Am J Epidemiol 2006; 164:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/36\">",
"      Palmer JR, Hatch EE, Rao RS, et al. Infertility among women exposed prenatally to diethylstilbestrol. Am J Epidemiol 2001; 154:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/37\">",
"      Missmer SA, Hankinson SE, Spiegelman D, et al. In utero exposures and the incidence of endometriosis. Fertil Steril 2004; 82:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/38\">",
"      DeCherney AH, Cholst I, Naftolin F. Structure and function of the fallopian tubes following exposure to diethylstilbestrol (DES) during gestation. Fertil Steril 1981; 36:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/39\">",
"      Kaufman RH, Adam E, Hatch EE, et al. Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring. Obstet Gynecol 2000; 96:483.",
"     </a>",
"    </li>",
"    <li>",
"     Swan, SH. Pregnancy outcome in DES daughters. In: Giusti, RM(ed). Report of the NIH Workshop on Long-Term Effects of Exposure to Diethylstilbestrol (DES). US Department of Health and Human Services, Public Health Service, National Institutes of health, Washington, DC 1992, p. 42.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/41\">",
"      Levine RU, Berkowitz KM. Conservative management and pregnancy outcome in diethylstilbestrol-exposed women with and without gross genital tract abnormalities. Am J Obstet Gynecol 1993; 169:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/42\">",
"      Wise LA, Palmer JR, Hatch EE, et al. Secondary sex ratio among women exposed to diethylstilbestrol in utero. Environ Health Perspect 2007; 115:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/43\">",
"      Verloop J, Rookus MA, van Leeuwen FE. Prevalence of gynecologic cancer in women exposed to diethylstilbestrol in utero. N Engl J Med 2000; 342:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/44\">",
"      Noller KL, Blair PB, O'Brien PC, et al. Increased occurrence of autoimmune disease among women exposed in utero to diethylstilbestrol. Fertil Steril 1988; 49:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/45\">",
"      Baird DD, Wilcox AJ, Herbst AL. Self-reported allergy, infection, and autoimmune diseases among men and women exposed in utero to diethylstilbestrol. J Clin Epidemiol 1996; 49:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/46\">",
"      Strohsnitter WC, Noller KL, Troisi R, et al. Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol. J Rheumatol 2010; 37:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/47\">",
"      Luster MI, Faith RE, McLachlan JA. Alterations of the antibody response following in utero exposure to diethylstilbestrol. Bull Environ Contam Toxicol 1978; 20:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/48\">",
"      Kebir O, Krebs MO. Diethylstilbestrol and risk of psychiatric disorders: a critical review and new insights. World J Biol Psychiatry 2012; 13:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/49\">",
"      Titus-Ernstoff L, Perez K, Hatch EE, et al. Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol. Epidemiology 2003; 14:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/50\">",
"      Wise LA, Palmer JR, Rowlings K, et al. Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. Obstet Gynecol 2005; 105:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/51\">",
"      Palmer JR, Herbst AL, Noller KL, et al. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: a cohort study. Environ Health 2009; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/52\">",
"      Wilcox AJ, Baird DD, Weinberg CR, et al. Fertility in men exposed prenatally to diethylstilbestrol. N Engl J Med 1995; 332:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/53\">",
"      Leary FJ, Resseguie LJ, Kurland LT, et al. Males exposed in utero to diethylstilbestrol. JAMA 1984; 252:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/54\">",
"      Vessey MP, Fairweather DV, Norman-Smith B, Buckley J. A randomized double-blind controlled trial of the value of stilboestrol therapy in pregnancy: long-term follow-up of mothers and their offspring. Br J Obstet Gynaecol 1983; 90:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/55\">",
"      Perez KM, Titus-Ernstoff L, Hatch EE, et al. Reproductive outcomes in men with prenatal exposure to diethylstilbestrol. Fertil Steril 2005; 84:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/56\">",
"      Wise LA, Titus-Ernstoff L, Palmer JR, et al. Time to pregnancy and secondary sex ratio in men exposed prenatally to diethylstilbestrol. Am J Epidemiol 2007; 166:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/57\">",
"      Bibbo M, Gill WB, Azizi F, et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol 1977; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/58\">",
"      Andonian RW, Kessler R. Transplacental exposure to diethylstilbestrol in men. Urology 1979; 13:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/59\">",
"      Depue RH, Pike MC, Henderson BE. Estrogen exposure during gestation and risk of testicular cancer. J Natl Cancer Inst 1983; 71:1151.",
"     </a>",
"    </li>",
"    <li>",
"     Moss, A, Osmond, D, Bacchetti, P, et al. Hormonal risk factors in testicular cancer: a case-control study. Am J Epidemiol 1986;124:39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/61\">",
"      Weir HK, Marrett LD, Kreiger N, et al. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. Int J Cancer 2000; 87:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/62\">",
"      Henderson BE, Benton B, Jing J, et al. Risk factors for cancer of the testis in young men. Int J Cancer 1979; 23:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/63\">",
"      Brown LM, Pottern LM, Hoover RN. Prenatal and perinatal risk factors for testicular cancer. Cancer Res 1986; 46:4812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/64\">",
"      Gershman ST, Stolley PD. A case-control study of testicular cancer using Connecticut tumour registry data. Int J Epidemiol 1988; 17:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/65\">",
"      Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst 2001; 93:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/66\">",
"      Schottenfeld D, Warshauer ME, Sherlock S, et al. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980; 112:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/67\">",
"      Newbold RR, Bullock BC, McLachlan JA. Testicular tumors in mice exposed in utero to diethylstilbestrol. J Urol 1987; 138:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/68\">",
"      Kaufman RH, Adam E. Findings in female offspring of women exposed in utero to diethylstilbestrol. Obstet Gynecol 2002; 99:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/69\">",
"      Titus-Ernstoff L, Troisi R, Hatch EE, et al. Menstrual and reproductive characteristics of women whose mothers were exposed in utero to diethylstilbestrol (DES). Int J Epidemiol 2006; 35:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/70\">",
"      Klip H, Verloop J, van Gool JD, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet 2002; 359:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/71\">",
"      Pons JC, Papiernik E, Billon A, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero. Prenat Diagn 2005; 25:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/72\">",
"      Palmer JR, Wise LA, Robboy SJ, et al. Hypospadias in sons of women exposed to diethylstilbestrol in utero. Epidemiology 2005; 16:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/73\">",
"      Felix JF, Steegers-Theunissen RP, de Walle HE, et al. Esophageal atresia and tracheoesophageal fistula in children of women exposed to diethylstilbestrol in utero. Am J Obstet Gynecol 2007; 197:38.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/74\">",
"      Titus-Ernstoff L, Troisi R, Hatch EE, et al. Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES). Int J Androl 2010; 33:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/75\">",
"      Titus-Ernstoff L, Troisi R, Hatch EE, et al. Offspring of women exposed in utero to diethylstilbestrol (DES): a preliminary report of benign and malignant pathology in the third generation. Epidemiology 2008; 19:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/76\">",
"      Newbold RR, Hanson RB, Jefferson WN, et al. Increased tumors but uncompromised fertility in the female descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis 1998; 19:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/77\">",
"      Newbold RR, Hanson RB, Jefferson WN, et al. Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis 2000; 21:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/15/3322/abstract/78\">",
"      Palmer JR, Anderson D, Helmrich SP, Herbst AL. Risk factors for diethylstilbestrol-associated clear cell adenocarcinoma. Obstet Gynecol 2000; 95:814.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cancer.org/Cancer/CancerCauses/OtherCarcinogens/MedicalTreatments/des-exposure (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     www.cancer.gov (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     CDC. DES update: health care providers. Information to identify and manage DES patients file://www.cdc.gov/des/hcp/information/women/index.html (Accessed on June 20, 2012).",
"    </li>",
"    <li>",
"     Clinician Information: DES Daughters - Women Exposed in Utero www.cancer.gov/cancertopics/causes/des/daughters-exposed-to-des (Accessed on July 11, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5427 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3322=[""].join("\n");
var outline_f3_15_3322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WOMEN WHO RECEIVED DES DURING PREGNANCY (DES MOTHERS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565946343\">",
"      Breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565955473\">",
"      Other cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565946350\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WOMEN EXPOSED TO DES IN-UTERO (DES DAUGHTERS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clear cell adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565955742\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565955984\">",
"      Other cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reproductive tract abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3247811\">",
"      - Uterus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3248013\">",
"      - Cervix and vagina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3248029\">",
"      - Adenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3248058\">",
"      - Vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Earlier menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pregnancy loss and preterm birth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Secondary sex ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7869954\">",
"      - Stillbirth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cervical squamous intraepithelial lesions (CIN) and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Psychological disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Benign gynecological tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MEN EXPOSED TO DES IN-UTERO (DES SONS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genitourinary abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Testicular and prostate cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      THIRD GENERATION EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565948378\">",
"      HEALTH CARE OF DES-EXPOSED INDIVIDUALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3248243\">",
"      Screening and surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19311257\">",
"      - DES mothers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19311264\">",
"      - DES daughters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19311271\">",
"      - DES sons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565948585\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565952241\">",
"      Women who received DES during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565952421\">",
"      Women exposed to DES in-utero",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565952954\">",
"      Men exposed to DES in-utero",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565952963\">",
"      Third generation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5427|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/6/11375\" title=\"figure 1A\">",
"      T shaped uterus 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/21/12639\" title=\"figure 1B\">",
"      T shaped uterus 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/12/16591\" title=\"figure 1C\">",
"      T shaped uterus 3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28261?source=related_link\">",
"      Screening for testicular cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_15_3323="HCV and blood test results";
var content_f3_15_3323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of HCV transmission based upon donor test results",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HCV 2.0 EIA* result",
"       </td>",
"       <td class=\"subtitle1\">",
"        Supplemental test (RIBA)&bull;",
"result",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability of HCV",
"transmission, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Not done",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Indeterminate",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Enzyme immunoassay.",
"     <br>",
"      &bull; Recombinant immunoblot assay.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Source: American Association of Blood Banks, HCV Lookback Information, September, 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3323=[""].join("\n");
var outline_f3_15_3323=null;
var title_f3_15_3324="Diff HBV genotypes B and C";
var content_f3_15_3324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and virological differences between genotype B and C",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genotype C",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genotype B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevalence of HBeAg",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous HBeAg seroconversion",
"       </td>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Early",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histological activity",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rate of progression to cirrhosis",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Risk of HCC",
"       </td>",
"       <td rowspan=\"2\">",
"        High",
"       </td>",
"       <td>",
"        Low (Japan, China)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variable (Taiwan)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency of PC variant (G1896A)",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency of CP variant (A1762T, G1764A)",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Response to IFN",
"       </td>",
"       <td rowspan=\"2\">",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (Similar in 1 study on PEG-IFN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Response to nucleotide(side) analogues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        On treatment",
"       </td>",
"       <td class=\"sublist_other\">",
"        Similar",
"       </td>",
"       <td class=\"sublist_other\">",
"        Similar",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anna SF Lok, MD and Chi-Jen Chu, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3324=[""].join("\n");
var outline_f3_15_3324=null;
var title_f3_15_3325="Vibrio isolates in the US over five years";
var content_f3_15_3325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Numbers of Vibrio infections by species, complications, and site of isolation in the United States from 2004-2009",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Clinical data",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Isolate data*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Patients",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hospitalizations",
"       </td>",
"       <td class=\"subtitle2\">",
"        Deaths",
"       </td>",
"       <td class=\"subtitle2\">",
"        Total",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Stool",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blood",
"       </td>",
"       <td class=\"subtitle2\">",
"        Wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V. cholerae (non-toxigenic)",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        228",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V. parahaemolyticus",
"       </td>",
"       <td>",
"        1007",
"       </td>",
"       <td>",
"        283",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        1013",
"       </td>",
"       <td>",
"        750",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        166",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V. vulnificus",
"       </td>",
"       <td>",
"        485",
"       </td>",
"       <td>",
"        417",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        532",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        321",
"       </td>",
"       <td>",
"        277",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        V. alginolyticus",
"       </td>",
"       <td>",
"        386",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        387",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        224",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. damsela",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V. fluvialis",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G. hollisae",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V. mimcus",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Numbers of non-toxigenic V. cholerae Vibrio infections in the US over five years, reported to the CDC from 2004 to 2009.",
"    <div class=\"footnotes\">",
"     * Other sites including ear, sputum, and urine not listed.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Includes isolates from different sites or of different species in the same patient.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from the Cholera and Other Vibrio Illness (COVIS) Annual Summary, 2009. Centers for Disease Control and Prevention. file://www.cdc.gov/nationalsurveillance/cholera_vibrio_surveillance.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3325=[""].join("\n");
var outline_f3_15_3325=null;
var title_f3_15_3326="Review genetic testing";
var content_f3_15_3326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The ACCE Model's list of targeted questions aimed at a comprehensive review of genetic testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Element",
"       </td>",
"       <td class=\"subtitle1\">",
"        Component",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific question",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        <strong>",
"         Disorder/setting",
"        </strong>",
"       </td>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1. What is the specific clinical disorder to be studied?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. What are the clinical findings defining this disorder?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. What is the clinical setting in which the test is to be performed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. What DNA test(s) are associated with this disorder?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Are preliminary screening questions employed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Is it a stand-alone test or is it one of a series of tests?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are only some tests performed on the basis of other results (series)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        <strong>",
"         Analytic validity",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8. Is the test qualitative or quantitative?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitivity",
"       </td>",
"       <td>",
"        9. How often is the test positive when a mutation is present?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specificity",
"       </td>",
"       <td>",
"        10. How often is the test negative when a mutation is not present?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        11. Is an internal QC program defined and externally monitored?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Have repeated measurements been made on specimens?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. What is the within- and between-laboratory precision?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14. If appropriate, how is confirmatory testing performed to resolve false positive results in a timely manner?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15. What range of patient specimens have been tested?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16. How often does the test fail to give a useable result?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17. How similar are results obtained in multiple laboratories using the same, or different, technology?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        <strong>",
"         Clinical validity",
"        </strong>",
"       </td>",
"       <td>",
"        Sensitivity",
"       </td>",
"       <td>",
"        18. How often is the test positive when the disorder is present?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specificity",
"       </td>",
"       <td>",
"        19. How often is the test negative when a disorder is not present?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        20. Are there methods to resolve clinical false positive results in a timely manner?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevalence",
"       </td>",
"       <td>",
"        21. What is the prevalence of the disorder in this setting?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        22. Has the test been adequately validated on all populations to which it may be offered?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23. What are the positive and negative predictive values?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24. What are the genotype/phenotype relationships?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25. What are the genetic, environmental or other modifiers?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"16\">",
"        <strong>",
"         Clinical utility",
"        </strong>",
"       </td>",
"       <td>",
"        Intervention",
"       </td>",
"       <td>",
"        26. What is the natural history of the disorder?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervention",
"       </td>",
"       <td>",
"        27. What is the impact of a positive (or negative) test on patient care?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervention",
"       </td>",
"       <td>",
"        28. If applicable, are diagnostic tests available?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervention",
"       </td>",
"       <td>",
"        29. Is there an effective remedy, acceptable action, or other measurable benefit?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervention",
"       </td>",
"       <td>",
"        30. Is there general access to that remedy or action?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        31. Is the test being offered to a socially vulnerable population?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quality assurance",
"       </td>",
"       <td>",
"        32. What quality assurance measures are in place?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pilot trials",
"       </td>",
"       <td>",
"        33. What are the results of pilot trials?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Health risks",
"       </td>",
"       <td>",
"        34. What health risks can be identified for follow-up testing and/or intervention?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        35. What are the financial costs associated with testing?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Economic",
"       </td>",
"       <td>",
"        36. What are the economic benefits associated with actions resulting from testing?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facilities",
"       </td>",
"       <td>",
"        37. What facilities/personnel are available or easily put in place?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Education",
"       </td>",
"       <td>",
"        38. What educational materials have been developed and validated and which of these are available?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        39. Are there informed consent requirements?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring",
"       </td>",
"       <td>",
"        40. What methods exist for long-term monitoring?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        41. What guidelines have been developed for evaluating program performance?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         ELSI",
"        </strong>",
"       </td>",
"       <td>",
"        Impediments",
"       </td>",
"       <td>",
"        42. What is known about stigmatization, discrimination, privacy/confidentiality and personal/family social issues?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        43. Are there legal issues regarding consent, ownership of data and/or samples, patents, licensing, proprietary testing, obligation to disclose, or reporting requirements?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Safeguards",
"       </td>",
"       <td>",
"        44. What safeguards have been described and are these safeguards in place and effective?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Haddow JE, Palomaki GE. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. In: Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Khoury, M, Little, J, Burke, W (Eds.), Oxford University Press 2003, p. 217.",
"     <br>",
"      Reproduced from Centers for Disease Control. Available at file://www.cdc.gov/genomics/gtesting/ACCE/acce_proj.htm#T1. Accessed on 2/24/2012.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3326=[""].join("\n");
var outline_f3_15_3326=null;
var title_f3_15_3327="Hurler kyphoscoliosis";
var content_f3_15_3327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kyphoscoliosis in mucopolysaccharidosis type I (MPS I, Hurler syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 150px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kyphoscoliosis in four-year-old male following bone marrow transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_15_3327=[""].join("\n");
var outline_f3_15_3327=null;
